Eli Lilly and (LLY) 10-Q 28 Apr 14 2014 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2014	Apr. 21, 2014
Document Information [Line Items]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	31-Mar-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q1	'
Entity Registrant Name	'Lilly Eli & Co	'
Entity Central Index Key	'0000059478	'
Current Fiscal Year End Date	'--12-31	'
Entity Well-known Seasoned Issuer	'Yes	'
Entity Voluntary Filers	'No	'
Entity Current Reporting Status	'Yes	'
Entity Filer Category	'Large Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	1,119,451,042

Consolidated_Condensed_Stateme

Consolidated Condensed Statements of Operations (USD $)	3 Months Ended
In Millions, except Per Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Revenue	$4,683.10	$5,602
Cost of sales	1,222.70	1,158.30
Research and development	1,109.30	1,348.10
Marketing, selling, and administrative	1,484.90	1,652
Asset impairment, restructuring, and other special charges	31.4	21.7
Other - net, (income) expense	-56	-529.2
Cost of sales, operating expenses, and other-net	3,792.30	3,650.90
Income before income taxes	890.8	1,951.10
Income taxes	162.9	403.1
Net income	$727.90	$1,548
Weighted-average number of common shares outstanding, including incremental shares	1,072.70	1,087.90
Basic earnings per share	$0.68	$1.42
Weighted-average number of common shares outstanding, including incremental shares and stock options	1,075.80	1,091.90
Diluted earnings per share	$0.68	$1.42
Dividends paid per share	$0.49	$0.49

Consolidated_Condensed_Stateme1

Consolidated Condensed Statements of Comprehensive Income (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Net income	$727.90	$1,548
Other comprehensive income (loss), net of tax	45.4	-217.3
Comprehensive income	$773.30	$1,330.70

Consolidated_Condensed_Balance

Consolidated Condensed Balance Sheets (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Current Assets	'	'
Cash and cash equivalents	$3,888	$3,830.20
Short-term investments	1,324.40	1,567.10
Accounts receivable, net of allowances of $61.8 (2014) and $62.2 (2013)	3,002.90	3,434.40
Other receivables	743.2	588.4
Inventories	2,969	2,928.80
Prepaid expenses and other	1,111.80	755.8
Total current assets	13,039.30	13,104.70
Other Assets	'	'
Investments	7,204.80	7,624.90
Goodwill and other intangibles, net	4,203.10	4,331.10
Sundry	2,339	2,212.50
Total other assets	13,746.90	14,168.50
Property and Equipment	'	'
Land, buildings, equipment, and construction in progress	15,779.60	15,646.70
Accumulated depreciation	-7,808.90	-7,671.20
Property and equipment, net	7,970.70	7,975.50
Total assets	34,756.90	35,248.70
Current Liabilities	'	'
Short-term borrowings and current maturities of long-term debt	9.1	1,012.60
Accounts payable	1,149.90	1,119.30
Employee compensation	554.8	943.9
Sales rebates and discounts	1,724.20	1,941.70
Dividends payable	0	523.5
Income taxes payable	102.5	254.4
Deferred income taxes	760.4	792.8
Other current liabilities	2,330.80	2,328.40
Total current liabilities	6,631.70	8,916.60
Other Liabilities	'	'
Long-term debt	5,255.30	4,200.30
Accrued retirement benefits	1,553.10	1,549.40
Long-term income taxes payable	906.6	1,078.70
Other noncurrent liabilities	2,061.50	1,863
Total other liabilities	9,776.50	8,691.40
Shareholders' Equity	'	'
Common stock	700.1	698.5
Additional paid-in capital	5,034.60	5,050
Retained earnings	17,665.30	16,992.40
Employee benefit trust	-3,013.20	-3,013.20
Accumulated other comprehensive loss	-1,957.30	-2,002.70
Cost of common stock in treasury	-91.4	-93.6
Total Eli Lilly and Company shareholders' equity	18,338.10	17,631.40
Noncontrolling interests	10.6	9.3
Total equity	18,348.70	17,640.70
Total liabilities and equity	$34,756.90	$35,248.70

Consolidated_Condensed_Balance1

Consolidated Condensed Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Allowances for doubtful accounts	$61.80	$62.20

Consolidated_Condensed_Stateme2

Consolidated Condensed Statements of Cash Flows (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Cash Flows from Operating Activities	'	'
Net income	$727,900,000	$1,548,000,000
Adjustments to Reconcile Net Income to Cash Flows from Operating Activities:	'	'
Depreciation and amortization	348,800,000	381,500,000
Change in deferred income taxes	-93,500,000	51,000,000
Stock-based compensation expense	38,300,000	35,200,000
Income related to the termination of the exenatide collaboration	0	-495,400,000
Other changes in operating assets and liabilities, net of acquisitions and divestitures	941,300,000	1,048,100,000
Other operating activities, net	5,100,000	9,200,000
Net Cash Provided by Operating Activities	272,300,000	379,400,000
Cash Flows from Investing Activities	'	'
Net purchases of property and equipment	-202,000,000	-157,900,000
Proceeds from sales and maturities of short-term investments	1,166,900,000	1,607,500,000
Purchases of short-term investments	-402,800,000	-313,100,000
Proceeds from sales and maturities of noncurrent investments	2,633,400,000	2,098,400,000
Purchases of noncurrent investments	-2,770,200,000	-1,861,400,000
Purchase of product rights	-25,000,000	0
Other investing activities, net	-11,900,000	-18,400,000
Net Cash Provided by Investing Activities	388,400,000	1,355,100,000
Cash Flows from Financing Activities	'	'
Dividends paid	-524,100,000	-531,100,000
Proceeds from issuance of long-term debt	992,900,000	0
Repayment of long-term debt	-1,002,000,000	-900,000
Purchases of common stock	-55,000,000	-1,198,100,000
Other financing activities, net	-6,900,000	0
Net Cash Used for Financing Activities	-595,100,000	-1,730,100,000
Effect of exchange rate changes on cash and cash equivalents	-7,800,000	-86,600,000
Net increase (decrease) in cash and cash equivalents	57,800,000	-82,200,000
Cash and cash equivalents at January 1	3,830,200,000	4,018,800,000
Cash and Cash Equivalents at March 31	$3,888,000,000	$3,936,600,000

Basis_of_Presentation

Basis of Presentation	3 Months Ended
	Mar. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Basis of Presentation [Text Block]	'
	Note 1: Basis of Presentation
	We have prepared the accompanying unaudited consolidated condensed financial statements in accordance with the requirements of Form 10-Q and, therefore, they do not include all information and footnotes necessary for a fair presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States (GAAP). In our opinion, the financial statements reflect all adjustments (including those that are normal and recurring) that are necessary for a fair presentation of the results of operations for the periods shown. In preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates.
	The information included in this Quarterly Report on Form 10-Q should be read in conjunction with our consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2013. We issued our financial statements by filing with the SEC and have evaluated subsequent events up to the time of the filing.
	Certain reclassifications have been made to prior periods in the consolidated condensed financial statements and accompanying notes to conform with the current presentation.
	All per-share amounts, unless otherwise noted in the footnotes, are presented on a diluted basis, that is, based on the weighted-average number of outstanding common shares plus the effect of dilutive stock options and other incremental shares.

Implementation_of_New_Financia

Implementation of New Financial Accounting Pronouncements	3 Months Ended
	Mar. 31, 2014
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]	'
Accounting Changes and Error Corrections [Text Block]	'
	Note 2: Implementation of New Financial Accounting Pronouncements
	In July 2013, the Financial Accounting Standards Board issued a clarification regarding the presentation of an unrecognized tax benefit related to a net operating loss carryforward, a similar tax loss, or a tax credit carryforward. Under this new standard, the liability related to an unrecognized tax benefit, or a portion thereof, should be presented in the financial statements as a reduction to a deferred tax asset if available under the tax law of the applicable jurisdiction to settle any additional income taxes that would result from the disallowance of a tax position. Otherwise, the unrecognized tax benefit should be presented in the financial statements as a separate liability. The assessment is based on the unrecognized tax benefit and deferred tax asset that exist at the reporting date. The provisions of the new standard are effective on a prospective basis beginning in 2014 for annual and interim reporting periods. Adoption of this standard in the first quarter of 2014 resulted in an immaterial impact to our consolidated condensed balance sheet as of March 31, 2014 and did not affect our consolidated condensed statements of operations.

Acquisitions

Acquisitions	3 Months Ended
	Mar. 31, 2014
Business Combinations [Abstract]	'
Acquisitions [Text Block]	'
	Note 3: Acquisitions
	In February 2014, we entered into an agreement to acquire Lohmann SE (Lohmann Animal Health), a privately-held company headquartered in Cuxhaven, Germany. Lohmann Animal Health is a global leader in poultry vaccines and also markets a range of feed additives. Under the terms of the agreement, we will acquire all assets of Lohmann SE and its subsidiary, Lohmann Animal Health, for approximately 440 million euro. As part of this transaction, we will acquire the rights to a range of vaccines and feed additives, commercial capabilities, and manufacturing sites in Germany and the United States. The transaction is expected to close in the second quarter of 2014, contingent upon clearance from regulatory authorities and other customary closing conditions.
	On April 22, 2014, we announced an agreement to acquire Novartis Animal Health. See Note 15 for additional details.

Collaborations

Collaborations	3 Months Ended
	Mar. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Collaborations [Text Block]	'
	Note 4: Collaborations and Other Arrangements
	We often enter into collaborative and other similar arrangements to develop and commercialize drug candidates. Collaborative activities may include research and development, marketing and selling (including promotional activities and physician detailing), manufacturing, and distribution. These arrangements often require milestone and royalty or profit-share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development, as well as expense reimbursements or payments to the third party. Revenues related to products we sell pursuant to these arrangements are included in net product sales, while other sources of revenue (e.g., royalties and profit-share payments) are included in collaboration and other revenue. For the three months ended March 31, 2014 and 2013, we recognized collaboration and other revenue of $181.2 million and $153.5 million, respectively. Operating expenses for costs incurred pursuant to these arrangements are reported in their respective expense line item, net of any payments made to or reimbursements received from our collaboration partners. Each collaboration is unique in nature, and our more significant arrangements are discussed below.
	Diabetes Collaboration
	We and Boehringer Ingelheim have a global agreement to jointly develop and commercialize a portfolio of diabetes compounds. Currently, the compounds included in the collaboration are Boehringer Ingelheim’s two oral diabetes agents, linagliptin and empagliflozin, and our new insulin glargine product. The agreement also provided Boehringer Ingelheim with the ability to opt in to the Phase III development and potential commercialization of our anti-TGF-beta monoclonal antibody. However, we made the decision in April 2014 to discontinue our development of the anti-TGF-beta monoclonal antibody, which had been in Phase II clinical testing.
	Linagliptin was approved in 2011 and launched in the U.S. (trade name Tradjenta®), Japan (trade name Trazenta™), certain countries in Europe (trade name Trajenta®), and other countries. Currently, empagliflozin and the new insulin glargine product have been submitted to regulatory authorities in the U.S., Europe, and Japan. During the first quarter of 2014, the U.S. Food and Drug Administration (FDA) issued a complete response letter for our New Drug Application (NDA) of empagliflozin in the United States. The FDA referenced previously observed deficiencies at a Boehringer Ingelheim facility where empagliflozin will be manufactured and stated these deficiencies need to be resolved before the approval of the application. We and Boehringer Ingelheim are committed to submitting a response to the complete response letter as soon as possible.
	In connection with the approval of linagliptin in the U.S., Japan, and Europe, we paid $478.7 million in success-based regulatory milestones, all of which were capitalized as intangible assets and are being amortized to cost of sales. We incurred milestone-related expenses of $97.2 million in connection with regulatory submissions for empagliflozin in the U.S., Europe, and Japan during 2013. These regulatory submission milestones were recorded as research and development expenses. We may also pay up to 225.0 million euro in additional success-based regulatory milestones for empagliflozin.
	During 2013, we earned $50.0 million in milestones for the regulatory submissions of our new insulin glargine product in the U.S., Europe, and Japan. These submission milestones were recorded as income in other–net, (income) expense. In the future, we will be eligible to receive up to $250.0 million in success-based regulatory milestones on our new insulin glargine product.
	The companies share ongoing development costs equally. The companies also share in the commercialization costs and gross margin for any product resulting from the collaboration that receives regulatory approval. We record our portion of the gross margin as collaboration and other revenue, and we record our portion of the commercialization costs as marketing, selling, and administrative expense. Each company will also be entitled to potential performance payments on sales of the molecules they contribute to the collaboration. Our revenue related to Trajenta was $76.9 million and $42.6 million for the quarters ended March 31, 2014 and 2013, respectively.
	Effient®
	We are in a collaborative arrangement with Daiichi Sankyo Co., Ltd. (Daiichi Sankyo) to develop, market, and promote Effient. We and Daiichi Sankyo co-promote Effient in certain territories (including the U.S. and five major European markets), while we have exclusive marketing rights in certain other territories. Daiichi Sankyo has exclusive marketing rights in Japan and certain other territories. The parties share approximately 50/50 in the profits, as well as in the costs of development and marketing in the co-promotion territories. A third party manufactures bulk product, and we produce the finished product for our exclusive and co-promotion territories. We record product sales in our exclusive and co-promotion territories. In our exclusive territories, we pay Daiichi Sankyo a royalty specific to these territories. Profit-share payments made to Daiichi Sankyo are recorded as marketing, selling, and administrative expenses. All royalties paid to Daiichi Sankyo and the third-party manufacturer are recorded in cost of sales. Effient sales were $119.3 million and $115.9 million for the quarters ended March 31, 2014 and 2013, respectively.
	Erbitux®
	We have several collaborations with respect to Erbitux. The most significant collaborations are in the U.S., Canada, and Japan (Bristol-Myers Squibb Company); and worldwide except the U.S. and Canada (Merck KGaA). Upon expiration of the agreements, all of the rights to Erbitux in the U.S. and Canada return to us and certain rights to Erbitux outside the U.S. and Canada will remain with Merck KGaA (Merck).
	The following table summarizes our revenue recognized with respect to Erbitux:
		Three Months Ended
		March 31,
		2014		2013
	Net product sales	$	13.2	$	25.3
	Collaboration and other revenue	77.7		69.6
	Total revenue	$	90.9	$	94.9
	Bristol-Myers Squibb Company
	Pursuant to commercial agreements with Bristol-Myers Squibb Company and E.R. Squibb (collectively, BMS), we are co-developing Erbitux in the U.S. and Canada with BMS through September 2018, exclusively, and in Japan with BMS and Merck through 2032. Under these arrangements, Erbitux research and development and other costs are shared by both companies according to a predetermined ratio.
	Responsibilities associated with clinical and other ongoing studies are apportioned between the parties under the agreements. Collaborative reimbursements received by us for supply of clinical trial materials; for research and development; and for a portion of marketing, selling, and administrative expenses are recorded as a reduction to the respective expense line items on the consolidated condensed statement of operations. We receive a distribution fee in the form of a royalty from BMS, based on a percentage of net sales in the U.S. and Canada, which is recorded in collaboration and other revenue. Royalty expense paid to third parties, net of any reimbursements received, is recorded as a reduction of collaboration and other revenue.
	We are responsible for the manufacture and supply of all requirements of Erbitux in bulk-form active pharmaceutical ingredient (API) for clinical and commercial use in the U.S. and Canada, and BMS will purchase all of its requirements of API for commercial use from us, subject to certain stipulations per the agreement. Sales of Erbitux to BMS for commercial use are reported in net product sales.
	Merck KGaA
	A development and license agreement grants Merck exclusive rights to market Erbitux outside of the U.S. and Canada, and expires in December 2018. A separate agreement grants co-exclusive rights among Merck, BMS, and us in Japan and expires in 2032.
	Merck manufactures Erbitux for supply in its territory as well as for Japan. We receive a royalty on the sales of Erbitux outside of the U.S. and Canada, which is included in collaboration and other revenue as earned. Royalty expense paid to third parties, net of any royalty reimbursements received, is recorded as a reduction of collaboration and other revenue.
	Exenatide
	In November 2011, we agreed with Amylin Pharmaceuticals, Inc. (Amylin) to terminate our collaborative arrangement for the joint development, marketing, and selling of Byetta® (exenatide injection) and other forms of exenatide such as Bydureon® (exenatide extended-release for injectable suspension). Under the terms of the termination agreement, Amylin made a one-time, upfront payment to us of $250.0 million. Amylin also agreed to make future revenue-sharing payments to us in an amount equal to 15.0 percent of its global net sales of exenatide products until Amylin made aggregate payments to us of $1.20 billion plus interest, which would accrue at 9.5 percent. Upon completion of the acquisition of Amylin by Bristol-Myers Squibb Company in August 2012, Amylin's obligation of $1.26 billion, including accrued interest, was paid in full, with $1.21 billion representing a prepayment of the obligation. We would also receive a $150.0 million milestone payment contingent upon FDA approval of a once-monthly suspension version of exenatide.
	Commercial operations were transferred to Amylin in the U.S. in late-2011. Outside the U.S., we transferred to Amylin exenatide commercial rights and control in all markets during the first quarter of 2013. We were responsible for certain development costs related to certain clinical trials outside the U.S. that we were conducting as of the date of the termination agreement as well as commercialization costs outside the U.S. until the commercial rights were transferred to Amylin.
	Payments received from Amylin were allocated 65 percent to the U.S., which was treated as a contract termination, and 35 percent to the business outside the U.S., which was treated as the disposition of a business. The allocation was based upon relative fair values. The revenue-sharing income allocated to the U.S. was recognized as collaboration and other revenue, consistent with our policy for royalty revenue, while the income related to the prepayment of Amylin's obligation allocated to the U.S. was recognized in other–net, (income) expense. All income allocated to the business outside the U.S. that was transferred during the first quarter of 2013 was recognized as a gain on the disposition of a business in other–net, (income) expense, net of the goodwill allocated to the business transferred.
	Under the terms of our prior arrangement, we reported as net product sales 100 percent of sales outside the U.S. and our sales of Byetta pen delivery devices to Amylin. We paid Amylin a percentage of the gross margin of exenatide sales outside of the U.S., and these costs were recorded in cost of sales. This arrangement for the commercial operations outside the U.S. continued until those rights were transferred to Amylin during the first quarter of 2013.
	In accordance with the prior arrangement and pursuant to Amylin’s request, we loaned Amylin $165.0 million in the second quarter of 2011. This loan and related accrued interest were paid in full in August 2012.
	The following table summarizes the revenue and other income recognized with respect to exenatide:
		Three Months Ended
		March 31,
		2014		2013
	Net product sales	$	7.6	$	64.1
	Income related to termination of the exenatide collaboration with Amylin (1)	—		495.4
	1 Presented in other-net, (income) expense
	Solanezumab
	We have an agreement with an affiliate of TPG-Axon Capital (TPG) whereby TPG funded a portion of the Phase III development of solanezumab. Under the agreement, TPG’s obligation to fund solanezumab costs was not material and ended in the first half of 2011. In exchange for their funding, TPG may receive success-based sales milestones totaling approximately $70 million and mid-single digit royalties contingent upon the successful development of solanezumab. The royalties would be paid for approximately 10 years after launch of a product.
	Baricitinib
	We have a worldwide license and collaboration agreement with Incyte Corporation (Incyte) which provides us the development and commercialization rights to its Janus tyrosine kinase (JAK) inhibitor compound, now known as baricitinib, and certain follow-on compounds, for the treatment of inflammatory and autoimmune diseases. Incyte has the right to receive tiered, double-digit royalty payments on future global sales with rates ranging up to 20 percent if the product is successfully commercialized. The agreement provides Incyte with options to co-develop these compounds on an indication-by-indication basis by funding 30 percent of the associated development costs from the initiation of a Phase IIb trial through regulatory approval in exchange for increased tiered royalties ranging up to percentages in the high twenties. In 2010, Incyte exercised its option to co-develop baricitinib in rheumatoid arthritis. The agreement also provides Incyte with an option to co-promote in the U.S. and calls for payments associated with certain development, success-based regulatory, and sales-based milestones. Upon initiation of Phase III trials for the treatment of rheumatoid arthritis in the fourth quarter of 2012, we incurred a milestone-related expense of $50.0 million which was recorded as research and development expense. As of March 31, 2014, Incyte is eligible to receive up to $415.0 million of additional payments from us contingent upon certain development and success-based regulatory milestones as well as an additional $150.0 million of potential sales-based milestones.
	Tanezumab
	In October 2013, we entered into a collaboration agreement with Pfizer Inc. (Pfizer) to jointly develop and globally commercialize tanezumab for the potential treatment of osteoarthritis pain, chronic low back pain and cancer pain. Tanezumab is currently in Phase III development and is subject to a partial clinical hold by the FDA pending submission of nonclinical data to the FDA. Under the agreement, the companies share equally the ongoing development costs and, if successful, in gross margins and commercialization expenses. Contingent upon the parties continuing in the collaboration after receipt of the FDA's response to the submission of the nonclinical data, we will be obligated to pay an upfront fee of $200.0 million. This payment would be immediately expensed. In addition to this fee, we may pay up to $350.0 million in success-based regulatory milestones and up to $1.23 billion in a series of sales-based milestones, contingent upon the commercial success of tanezumab. Both parties have the right to terminate the agreement under certain circumstances.
	Summary of Collaboration-Related Commission and Profit-Share Payments
	The aggregate amount of commission and profit-share payments included in marketing, selling, and administrative expense pursuant to the collaborations described above was $48.0 million and $45.2 million for the quarters ended March 31, 2014 and 2013, respectively.
	Amortization of Intangible Assets
	We record, as finite-lived intangible assets, the cost of milestone payments associated with products approved for marketing, as well as the cost of rights to assets approved for marketing that were acquired in business combinations. We also record finite-lived intangible assets for the cost of licensed platform technologies that have alternative future uses in research and development; manufacturing technologies; and customer relationships from business combinations. Amortization expense related to these finite-lived intangibles was $131.9 million and $146.1 million for the quarters ended March 31, 2014 and 2013, respectively.
	Note 4: Collaborations and Other Arrangements
	We often enter into collaborative and other similar arrangements to develop and commercialize drug candidates. Collaborative activities may include research and development, marketing and selling (including promotional activities and physician detailing), manufacturing, and distribution. These arrangements often require milestone and royalty or profit-share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development, as well as expense reimbursements or payments to the third party. Revenues related to products we sell pursuant to these arrangements are included in net product sales, while other sources of revenue (e.g., royalties and profit-share payments) are included in collaboration and other revenue. For the three months ended March 31, 2014 and 2013, we recognized collaboration and other revenue of $181.2 million and $153.5 million, respectively. Operating expenses for costs incurred pursuant to these arrangements are reported in their respective expense line item, net of any payments made to or reimbursements received from our collaboration partners. Each collaboration is unique in nature, and our more significant arrangements are discussed below.
	Diabetes Collaboration
	We and Boehringer Ingelheim have a global agreement to jointly develop and commercialize a portfolio of diabetes compounds. Currently, the compounds included in the collaboration are Boehringer Ingelheim’s two oral diabetes agents, linagliptin and empagliflozin, and our new insulin glargine product. The agreement also provided Boehringer Ingelheim with the ability to opt in to the Phase III development and potential commercialization of our anti-TGF-beta monoclonal antibody. However, we made the decision in April 2014 to discontinue our development of the anti-TGF-beta monoclonal antibody, which had been in Phase II clinical testing.
	Linagliptin was approved in 2011 and launched in the U.S. (trade name Tradjenta®), Japan (trade name Trazenta™), certain countries in Europe (trade name Trajenta®), and other countries. Currently, empagliflozin and the new insulin glargine product have been submitted to regulatory authorities in the U.S., Europe, and Japan. During the first quarter of 2014, the U.S. Food and Drug Administration (FDA) issued a complete response letter for our New Drug Application (NDA) of empagliflozin in the United States. The FDA referenced previously observed deficiencies at a Boehringer Ingelheim facility where empagliflozin will be manufactured and stated these deficiencies need to be resolved before the approval of the application. We and Boehringer Ingelheim are committed to submitting a response to the complete response letter as soon as possible.
	In connection with the approval of linagliptin in the U.S., Japan, and Europe, we paid $478.7 million in success-based regulatory milestones, all of which were capitalized as intangible assets and are being amortized to cost of sales. We incurred milestone-related expenses of $97.2 million in connection with regulatory submissions for empagliflozin in the U.S., Europe, and Japan during 2013. These regulatory submission milestones were recorded as research and development expenses. We may also pay up to 225.0 million euro in additional success-based regulatory milestones for empagliflozin.
	During 2013, we earned $50.0 million in milestones for the regulatory submissions of our new insulin glargine product in the U.S., Europe, and Japan. These submission milestones were recorded as income in other–net, (income) expense. In the future, we will be eligible to receive up to $250.0 million in success-based regulatory milestones on our new insulin glargine product.
	The companies share ongoing development costs equally. The companies also share in the commercialization costs and gross margin for any product resulting from the collaboration that receives regulatory approval. We record our portion of the gross margin as collaboration and other revenue, and we record our portion of the commercialization costs as marketing, selling, and administrative expense. Each company will also be entitled to potential performance payments on sales of the molecules they contribute to the collaboration. Our revenue related to Trajenta was $76.9 million and $42.6 million for the quarters ended March 31, 2014 and 2013, respectively.
	Effient®
	We are in a collaborative arrangement with Daiichi Sankyo Co., Ltd. (Daiichi Sankyo) to develop, market, and promote Effient. We and Daiichi Sankyo co-promote Effient in certain territories (including the U.S. and five major European markets), while we have exclusive marketing rights in certain other territories. Daiichi Sankyo has exclusive marketing rights in Japan and certain other territories. The parties share approximately 50/50 in the profits, as well as in the costs of development and marketing in the co-promotion territories. A third party manufactures bulk product, and we produce the finished product for our exclusive and co-promotion territories. We record product sales in our exclusive and co-promotion territories. In our exclusive territories, we pay Daiichi Sankyo a royalty specific to these territories. Profit-share payments made to Daiichi Sankyo are recorded as marketing, selling, and administrative expenses. All royalties paid to Daiichi Sankyo and the third-party manufacturer are recorded in cost of sales. Effient sales were $119.3 million and $115.9 million for the quarters ended March 31, 2014 and 2013, respectively.
	Erbitux®
	We have several collaborations with respect to Erbitux. The most significant collaborations are in the U.S., Canada, and Japan (Bristol-Myers Squibb Company); and worldwide except the U.S. and Canada (Merck KGaA). Upon expiration of the agreements, all of the rights to Erbitux in the U.S. and Canada return to us and certain rights to Erbitux outside the U.S. and Canada will remain with Merck KGaA (Merck).
	The following table summarizes our revenue recognized with respect to Erbitux:
		Three Months Ended
	March 31,
	2014		2013
Net product sales	$	13.2	$	25.3
Collaboration and other revenue	77.7		69.6
Total revenue	$	90.9	$	94.9
Bristol-Myers Squibb Company
Pursuant to commercial agreements with Bristol-Myers Squibb Company and E.R. Squibb (collectively, BMS), we are co-developing Erbitux in the U.S. and Canada with BMS through September 2018, exclusively, and in Japan with BMS and Merck through 2032. Under these arrangements, Erbitux research and development and other costs are shared by both companies according to a predetermined ratio.
Responsibilities associated with clinical and other ongoing studies are apportioned between the parties under the agreements. Collaborative reimbursements received by us for supply of clinical trial materials; for research and development; and for a portion of marketing, selling, and administrative expenses are recorded as a reduction to the respective expense line items on the consolidated condensed statement of operations. We receive a distribution fee in the form of a royalty from BMS, based on a percentage of net sales in the U.S. and Canada, which is recorded in collaboration and other revenue. Royalty expense paid to third parties, net of any reimbursements received, is recorded as a reduction of collaboration and other revenue.
We are responsible for the manufacture and supply of all requirements of Erbitux in bulk-form active pharmaceutical ingredient (API) for clinical and commercial use in the U.S. and Canada, and BMS will purchase all of its requirements of API for commercial use from us, subject to certain stipulations per the agreement. Sales of Erbitux to BMS for commercial use are reported in net product sales.
Merck KGaA
A development and license agreement grants Merck exclusive rights to market Erbitux outside of the U.S. and Canada, and expires in December 2018. A separate agreement grants co-exclusive rights among Merck, BMS, and us in Japan and expires in 2032.
Merck manufactures Erbitux for supply in its territory as well as for Japan. We receive a royalty on the sales of Erbitux outside of the U.S. and Canada, which is included in collaboration and other revenue as earned. Royalty expense paid to third parties, net of any royalty reimbursements received, is recorded as a reduction of collaboration and other revenue.
Exenatide
In November 2011, we agreed with Amylin Pharmaceuticals, Inc. (Amylin) to terminate our collaborative arrangement for the joint development, marketing, and selling of Byetta® (exenatide injection) and other forms of exenatide such as Bydureon® (exenatide extended-release for injectable suspension). Under the terms of the termination agreement, Amylin made a one-time, upfront payment to us of $250.0 million. Amylin also agreed to make future revenue-sharing payments to us in an amount equal to 15.0 percent of its global net sales of exenatide products until Amylin made aggregate payments to us of $1.20 billion plus interest, which would accrue at 9.5 percent. Upon completion of the acquisition of Amylin by Bristol-Myers Squibb Company in August 2012, Amylin's obligation of $1.26 billion, including accrued interest, was paid in full, with $1.21 billion representing a prepayment of the obligation. We would also receive a $150.0 million milestone payment contingent upon FDA approval of a once-monthly suspension version of exenatide.
Commercial operations were transferred to Amylin in the U.S. in late-2011. Outside the U.S., we transferred to Amylin exenatide commercial rights and control in all markets during the first quarter of 2013. We were responsible for certain development costs related to certain clinical trials outside the U.S. that we were conducting as of the date of the termination agreement as well as commercialization costs outside the U.S. until the commercial rights were transferred to Amylin.
Payments received from Amylin were allocated 65 percent to the U.S., which was treated as a contract termination, and 35 percent to the business outside the U.S., which was treated as the disposition of a business. The allocation was based upon relative fair values. The revenue-sharing income allocated to the U.S. was recognized as collaboration and other revenue, consistent with our policy for royalty revenue, while the income related to the prepayment of Amylin's obligation allocated to the U.S. was recognized in other–net, (income) expense. All income allocated to the business outside the U.S. that was transferred during the first quarter of 2013 was recognized as a gain on the disposition of a business in other–net, (income) expense, net of the goodwill allocated to the business transferred.
Under the terms of our prior arrangement, we reported as net product sales 100 percent of sales outside the U.S. and our sales of Byetta pen delivery devices to Amylin. We paid Amylin a percentage of the gross margin of exenatide sales outside of the U.S., and these costs were recorded in cost of sales. This arrangement for the commercial operations outside the U.S. continued until those rights were transferred to Amylin during the first quarter of 2013.
In accordance with the prior arrangement and pursuant to Amylin’s request, we loaned Amylin $165.0 million in the second quarter of 2011. This loan and related accrued interest were paid in full in August 2012.
The following table summarizes the revenue and other income recognized with respect to exenatide:
	Three Months Ended
	March 31,
	2014		2013
Net product sales	$	7.6	$	64.1
Income related to termination of the exenatide collaboration with Amylin (1)	—		495.4
1 Presented in other-net, (income) expense
Solanezumab
We have an agreement with an affiliate of TPG-Axon Capital (TPG) whereby TPG funded a portion of the Phase III development of solanezumab. Under the agreement, TPG’s obligation to fund solanezumab costs was not material and ended in the first half of 2011. In exchange for their funding, TPG may receive success-based sales milestones totaling approximately $70 million and mid-single digit royalties contingent upon the successful development of solanezumab. The royalties would be paid for approximately 10 years after launch of a product.
Baricitinib
We have a worldwide license and collaboration agreement with Incyte Corporation (Incyte) which provides us the development and commercialization rights to its Janus tyrosine kinase (JAK) inhibitor compound, now known as baricitinib, and certain follow-on compounds, for the treatment of inflammatory and autoimmune diseases. Incyte has the right to receive tiered, double-digit royalty payments on future global sales with rates ranging up to 20 percent if the product is successfully commercialized. The agreement provides Incyte with options to co-develop these compounds on an indication-by-indication basis by funding 30 percent of the associated development costs from the initiation of a Phase IIb trial through regulatory approval in exchange for increased tiered royalties ranging up to percentages in the high twenties. In 2010, Incyte exercised its option to co-develop baricitinib in rheumatoid arthritis. The agreement also provides Incyte with an option to co-promote in the U.S. and calls for payments associated with certain development, success-based regulatory, and sales-based milestones. Upon initiation of Phase III trials for the treatment of rheumatoid arthritis in the fourth quarter of 2012, we incurred a milestone-related expense of $50.0 million which was recorded as research and development expense. As of March 31, 2014, Incyte is eligible to receive up to $415.0 million of additional payments from us contingent upon certain development and success-based regulatory milestones as well as an additional $150.0 million of potential sales-based milestones.
Tanezumab
In October 2013, we entered into a collaboration agreement with Pfizer Inc. (Pfizer) to jointly develop and globally commercialize tanezumab for the potential treatment of osteoarthritis pain, chronic low back pain and cancer pain. Tanezumab is currently in Phase III development and is subject to a partial clinical hold by the FDA pending submission of nonclinical data to the FDA. Under the agreement, the companies share equally the ongoing development costs and, if successful, in gross margins and commercialization expenses. Contingent upon the parties continuing in the collaboration after receipt of the FDA's response to the submission of the nonclinical data, we will be obligated to pay an upfront fee of $200.0 million. This payment would be immediately expensed. In addition to this fee, we may pay up to $350.0 million in success-based regulatory milestones and up to $1.23 billion in a series of sales-based milestones, contingent upon the commercial success of tanezumab. Both parties have the right to terminate the agreement under certain circumstances.
Summary of Collaboration-Related Commission and Profit-Share Payments
The aggregate amount of commission and profit-share payments included in marketing, selling, and administrative expense pursuant to the collaborations described above was $48.0 million and $45.2 million for the quarters ended March 31, 2014 and 2013, respectively.
Amortization of Intangible Assets
We record, as finite-lived intangible assets, the cost of milestone payments associated with products approved for marketing, as well as the cost of rights to assets approved for marketing that were acquired in business combinations. We also record finite-lived intangible assets for the cost of licensed platform technologies that have alternative future uses in research and development; manufacturing technologies; and customer relationships from business combinations. Amortization expense related to these finite-lived intangibles was $131.9 million and $146.1 million for the quarters ended March 31, 2014 and 2013, respectively.

Asset_Impairments_Restructurin

Asset Impairments, Restructuring, and Other Special Charges	3 Months Ended
	Mar. 31, 2014
Extraordinary and Unusual Items [Abstract]	'
Unusual or Infrequent Items Disclosure [Text Block]	'
	Note 5: Asset Impairment, Restructuring, and Other Special Charges
	We recognized asset impairment, restructuring, and other special charges of $31.4 million and $21.7 million during the three months ended March 31, 2014 and 2013, respectively. The charges for both quarters related primarily to costs for actions taken to reduce our cost structure.

Financial_Instruments

Financial Instruments	3 Months Ended
	Mar. 31, 2014
Fair Value Disclosures [Abstract]	'
Financial Instruments [Text Block]	'
	Note 6: Financial Instruments
	Financial instruments that potentially subject us to credit risk consist principally of trade receivables and interest-bearing investments. Wholesale distributors of life-sciences products account for a substantial portion of trade receivables; collateral is generally not required. The risk associated with this concentration is mitigated by our ongoing credit-review procedures and insurance. A large portion of our cash is held by a few major financial institutions. We monitor our exposures with these institutions and do not expect any of these institutions to fail to meet their obligations. Major financial institutions represent the largest component of our investments in corporate debt securities. In accordance with documented corporate policies, we monitor the amount of credit exposure to any one financial institution or corporate issuer. We are exposed to credit-related losses in the event of nonperformance by counterparties to risk-management instruments but do not expect any counterparties to fail to meet their obligations given their high credit ratings.
	Accounting Policy for Risk-Management Instruments
	Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and do not create additional risk because gains and losses on derivative contracts offset losses and gains on the assets, liabilities, and transactions being hedged. As derivative contracts are initiated, we designate each instrument as either a fair value hedge or a cash flow hedge. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis.
	For derivative contracts that are designated and qualify as fair value hedges, the derivative instrument is marked to market with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative contracts that are designated and qualify as cash flow hedges, the effective portion of gains and losses on these contracts is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same period the hedged transaction affects earnings. Hedge ineffectiveness is immediately recognized in earnings. Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized in current earnings during the period of change.
	We may enter into foreign currency forward contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, the British pound, and the Japanese yen). Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures. Forward contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other–net, (income) expense. We may enter into foreign currency forward contracts and currency swaps as fair value hedges of firm commitments. Forward contracts generally have maturities not exceeding 12 months. At March 31, 2014, we had outstanding foreign currency forward commitments to purchase 290.4 million U.S. dollars and sell 209.9 million euro, commitments to purchase 422.7 million euro and sell 585.8 million U.S. dollars, commitments to purchase 269.2 million U.S. dollars and sell 27.47 billion Japanese yen, and commitments to purchase 100.6 million British pounds and sell 120.2 million euro, which will all settle within 30 days.
	In the normal course of business, our operations are exposed to fluctuations in interest rates which can vary the costs of financing, investing, and operating. We address a portion of these risks through a controlled program of risk management that includes the use of derivative financial instruments. The objective of controlling these risks is to limit the impact of fluctuations in interest rates on earnings. Our primary interest-rate risk exposure results from changes in short-term U.S. dollar interest rates. In an effort to manage interest-rate exposures, we strive to achieve an acceptable balance between fixed- and floating-rate debt and investment positions and may enter into interest rate swaps or collars to help maintain that balance.
	Interest rate swaps or collars that convert our fixed-rate debt to a floating rate are designated as fair value hedges of the underlying instruments. Interest rate swaps or collars that convert floating-rate debt to a fixed rate are designated as cash flow hedges. Interest expense on the debt is adjusted to include the payments made or received under the swap agreements. At March 31, 2014, substantially all of our total debt is at a fixed rate. We have converted approximately 50 percent of our fixed-rate debt to floating rates through the use of interest rate swaps.
	We may enter into forward contracts and designate them as cash flow hedges to limit the potential volatility of earnings and cash flow associated with forecasted sales of available-for-sale securities.
	We may enter into forward-starting interest rate swaps as part of any anticipated future debt issuance in order to reduce the risk of cash flow volatility from future changes in interest rates. Upon completion of a debt issuance and termination of the swap, the change in fair value of these instruments is recorded as part of other comprehensive income (loss) and is amortized to interest expense over the life of the debt agreement.
	The Effect of Risk-Management Instruments on the Consolidated Condensed Statement of Operations
	The following effects of risk-management instruments were recognized in other–net, (income) expense:
		Three Months Ended
		March 31,
		2014			2013
	Fair value hedges:
	Effect from hedged fixed-rate debt	$	51.8		$	(69.0	)
	Effect from interest rate contracts	(51.8		)	69
	Cash flow hedges:
	Effective portion of losses on equity contracts reclassified from accumulated other comprehensive loss(1)	39.5			—
	Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss	2.2			2.2
	Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments	(0.3		)	0.1
	1 Realized gains on the sale of the underlying equity securities recognized in other–net, (income) expense for the three months ended March 31, 2014 were $69.0 million.
	The effective portion of net gains on equity contracts in designated cash flow hedging relationships recorded in other comprehensive income (loss) was $85.9 million and $1.1 million for the three months ended March 31, 2014 and 2013, respectively. During the next nine months, we expect to sell the underlying equity securities in designated cash flow hedging relationships that were outstanding at March 31, 2014, and will reclassify to earnings the accumulated other comprehensive loss related to the cash flow hedges and the unrealized gains on the underlying equity securities. The unrealized gains are in excess of the losses on the cash flow hedges.
	During the next 12 months, we expect to reclassify from accumulated other comprehensive loss to earnings $9.0 million of pretax net losses on cash flow hedges of the variability in expected future interest payments on our floating rate debt.
	During the three months ended March 31, 2014 and 2013, net losses related to ineffectiveness, as well as net losses related to the portion of our risk-management hedging instruments, fair value hedges, and cash flow hedges that were excluded from the assessment of effectiveness, were not material.
	Fair Value of Financial Instruments
	The following tables summarize certain fair value information at March 31, 2014 and December 31, 2013 for assets and liabilities measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments:
									Fair Value Measurements Using
	Description	Carrying			Amortized				Quoted Prices in Active Markets for Identical Assets			Significant Other			Significant		Fair
		Amount			Cost				(Level 1)			Observable Inputs			Unobservable		Value
												(Level 2)			Inputs
															(Level 3)
	March 31, 2014
	Cash and cash equivalents	$	3,888.00		$	3,888.00			$	3,668.20		$	219.8		$		$	3,888.00
	Short-term investments:
	Government-related debt securities:
	U.S. government and agencies	$	151.1		$	151			$	151.1		$			$		$	151.1
	Foreign and other	106.8			106.8							106.8					106.8
	Corporate debt securities	841.8			838.9							841.8					841.8
	Other securities	2.5			2.5							2.5					2.5
	Marketable equity	222.2			56.3				222.2								222.2
	Short-term investments	$	1,324.40		$	1,155.50
	Noncurrent investments:
	Government-related debt securities:
	U.S. government and agencies	$	854		$	860.3			$	843.2		$	10.8		$		$	854
	Foreign and other	122.7			122.7							122.7					122.7
	Corporate debt securities	4,569.50			4,545.50							4,569.50					4,569.50
	Mortgage-backed	631.9			644							631.9					631.9
	Asset-backed	541.8			546							541.8					541.8
	Other securities	7.6			8.2							7.6					7.6
	Marketable equity	108.7			22.8				108.7								108.7
	Equity method and other investments(1)	368.6			368.6
	Noncurrent investments	$	7,204.80		$	7,118.10
	December 31, 2013
	Cash and cash equivalents	$	3,830.20		$	3,830.20			$	3,772.60		$	57.6		$		$	3,830.20
	Short-term investments:
	U.S. government and agencies	$	276.4		$	276.6			$	276.4		$			$		$	276.4
	Corporate debt securities	931.7			929.8							931.7					931.7
	Other securities	2.7			2.7							2.7					2.7
	Marketable equity	356.3			75				356.3								356.3
	Short-term investments	$	1,567.10		$	1,284.10
	Noncurrent investments:
U.S. government and agencies	$	1,115.60		$	1,126.10			$	1,035.60		$	80		$		$	1,115.60
Corporate debt securities	4,940.50			4,933.70							4,940.50					4,940.50
Mortgage-backed	636			652.4							636					636
Asset-backed	490			494.5							490					490
Other securities	7.3			8.3							7.3					7.3
Marketable equity	81.2			22.8				81.2								81.2
Equity method and other investments(1)	354.3			354.3
Noncurrent investments	$	7,624.90		$	7,592.10
1 Fair value not applicable
				Fair Value Measurements Using
Description	Carrying			Quoted Prices in Active Markets for Identical Assets		Significant				Significant	Fair
	Amount			(Level 1)		Other Observable Inputs				Unobservable	Value
						(Level 2)				Inputs
										(Level 3)
Long-term debt, including current portion
March 31, 2014	$	(5,264.4	)	$		$	(5,595.5	)		$	$	(5,595.5	)
31-Dec-13	(5,212.9		)			(5,490.9		)			(5,490.9		)
				Fair Value Measurements Using
Description	Carrying			Quoted Prices in Active Markets for Identical Assets		Significant				Significant	Fair
	Amount			(Level 1)		Other Observable Inputs				Unobservable	Value
						(Level 2)				Inputs
										(Level 3)
March 31, 2014
Risk-management instruments
Interest rate contracts designated as hedging instruments:
Sundry	$	334.1				$	334.1				$	334.1
Other noncurrent liabilities	(1.2		)			(1.2		)			(1.2		)
Foreign exchange contracts not designated as hedging instruments:
Other receivables	6.4					6.4					6.4
Other current liabilities	(8.0		)			(8.0		)			(8.0		)
Equity contracts designated as hedging instruments:
Other current liabilities	(63.7		)			(63.7		)			(63.7		)
December 31, 2013
Risk-management instruments
Interest rate contracts designated as hedging instruments:
Other receivables	20.1					20.1					20.1
Sundry	278.7					278.7					278.7
Other noncurrent liabilities	(0.9		)			(0.9		)			(0.9		)
Foreign exchange contracts not designated as hedging instruments:
Other receivables	6.7					6.7					6.7
Other current liabilities	(7.1		)			(7.1		)			(7.1		)
Equity contracts designated as hedging instruments:
Other current liabilities	(149.6		)			(149.6		)			(149.6		)
Risk-management instruments above are disclosed on a gross basis. There are various rights of setoff associated with certain of the risk-management instruments above that are subject to an enforceable master netting arrangement or similar agreements. Although various rights of setoff and master netting arrangements or similar agreements may exist with the individual counterparties to the risk-management instruments above, individually, these financial rights are not material.
We determine fair values based on a market approach using quoted market values, significant other observable inputs for identical or comparable assets or liabilities, or discounted cash flow analyses. The fair value of equity method investments and other investments is not readily available.
In February 2014, we issued $600.0 million of 1.95% and $400.0 million of 4.65% fixed-rate notes with interest to be paid semi-annually and maturity dates of March 15, 2019, and June 15, 2044, respectively. Current maturities of long-term debt of $1.00 billion were repaid in March 2014.
The table below summarizes the contractual maturities of our investments in debt securities measured at fair value as of March 31, 2014:
	Maturities by Period
	Total			Less Than				5-Feb			10-Jun			More Than
				1 Year				Years			Years			10 Years
Fair value of debt securities	$	7,829.70		$	1,102.20			$	5,304.30		$	662.2		$	761
A summary of the fair value of available-for-sale securities in an unrealized gain or loss position and the amount of unrealized gains and losses (pretax) in accumulated other comprehensive loss follows:
	March 31, 2014			December 31, 2013
Unrealized gross gains	$	293.9		$	375.6
Unrealized gross losses	38.3			59.8
Fair value of securities in an unrealized gain position	5,356.00			4,982.70
Fair value of securities in an unrealized loss position	2,607.60			3,664.70
There were no other-than-temporary impairment losses on investment securities recognized in the consolidated condensed statement of operations for the three months ended March 31, 2014, compared with $5.2 million for the same period in 2013. For fixed-income securities, the amount of credit losses represents the difference between the present value of cash flows expected to be collected on these securities and the amortized cost. Factors considered in assessing the credit loss were the position in the capital structure, vintage and amount of collateral, delinquency rates, current credit support, and geographic concentration.
The securities in an unrealized loss position include fixed-rate debt securities of varying maturities. The value of fixed-income securities is sensitive to changes in the yield curve and other market conditions. Approximately 85 percent of the securities in a loss position are investment-grade debt securities. At this time, there is no indication of default on interest or principal payments for debt securities other than those for which an other-than-temporary impairment charge has been recorded. We do not intend to sell and it is not more likely than not we will be required to sell the securities in a loss position before the market values recover or the underlying cash flows have been received, and we have concluded that no additional other-than-temporary loss is required to be charged to earnings as of March 31, 2014.
Activity related to our investment portfolio, substantially all of which related to available-for-sale securities, was as follows:
	Three Months Ended
	March 31,
	2014			2013
Proceeds from sales	$	3,742.20		$	3,705.90
Realized gross gains on sales	79.8			10
Realized gross losses on sales	4			2.5
Realized gains and losses on sales of investments are computed based upon specific identification of the initial cost adjusted for any other-than-temporary declines in fair value that were recorded in earnings.

StockBased_Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2014
Employee Service Share-based Compensation, Aggregate Disclosures [Abstract]	'
Stock-Based Compensation [Text Block]	'
	Note 7: Stock-Based Compensation
	Our stock-based compensation expense consists of performance awards (PAs), shareholder value awards (SVAs), and restricted stock units (RSUs). We recognized pretax stock-based compensation expense of $38.3 million and $35.2 million for the three months ended March 31, 2014 and 2013, respectively.
	PAs are granted to officers and management and are payable in shares of our common stock. The number of PA shares actually issued, if any, varies depending on the achievement of certain pre-established earnings-per-share targets over a two-year period. PA shares are accounted for at fair value based upon the closing stock price on the date of grant and fully vest at the end of the measurement periods. As of March 31, 2014, the total remaining unrecognized compensation cost related to nonvested PAs was $49.7 million, which will be amortized over the weighted-average remaining requisite service period of 17 months.
	SVAs are granted to officers and management and are payable in shares of common stock at the end of a three-year period. The number of shares actually issued, if any, varies depending on our stock price at the end of the three-year vesting period compared to pre-established target stock prices. We measure the fair value of the SVA unit on the grant date using a Monte Carlo simulation model. The model utilizes multiple input variables that determine the probability of satisfying the market condition stipulated in the award grant and calculates the fair value of the award. As of March 31, 2014, the total remaining unrecognized compensation cost related to nonvested SVAs was $95.1 million, which will be amortized over the weighted-average remaining requisite service period of 26 months.
	RSUs are granted to certain employees and are payable in shares of our common stock. RSU shares are accounted for at fair value based upon the closing stock price on the date of grant. The corresponding expense is amortized over the vesting period, typically three years. As of March 31, 2014, the total remaining unrecognized compensation cost related to nonvested RSUs was $103.0 million, which will be amortized over the weighted-average remaining requisite service period of 27 months.

Shareholders_Equity

Shareholders' Equity	3 Months Ended
	Mar. 31, 2014
Equity, Class of Treasury Stock [Line Items]	'
Stockholders' Equity Note Disclosure [Text Block]	'
	Note 8: Shareholders’ Equity
	During the first quarter of 2014, we purchased $55.0 million of shares associated with our previously announced $5.00 billion share repurchase program. During the first quarter of 2013, we purchased the remaining $1.10 billion of shares associated with our $1.50 billion share repurchase program.

Income_Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2014
Income Tax Disclosure [Abstract]	'
Income Taxes [Text Block]	'
	Note 9: Income Taxes
	The U.S. examinations related to tax years 2010-2012 commenced during the fourth quarter of 2013. Because the examination of tax years 2010-2012 is still in the early stages, the resolution of matters in this audit period will likely extend beyond the next 12 months.

Retirement_Benefits

Retirement Benefits	3 Months Ended
	Mar. 31, 2014
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]	'
Retirement Benefits [Text Block]	'
	Note 10: Retirement Benefits
	Net pension and retiree health benefit expense included the following components:
		Defined Benefit Pension Plans						Retiree Health Benefit Plans
		Three Months Ended						Three Months Ended
		March 31,						March 31,
		2014			2013			2014			2013
	Components of net periodic benefit cost:
	Service cost	$	62.7		$	69.7		$	11.3		$	15.1
	Interest cost	119.2			109.4			21.2			23.4
	Expected return on plan assets	(189.3		)	(174.9		)	(36.0		)	(32.8		)
	Amortization of prior service cost (benefit)	0.9			2.6			(7.3		)	(6.9		)
	Recognized actuarial loss	69.1			96			5.1			23
	Net periodic benefit cost (benefit)	$	62.6		$	102.8		$	(5.7	)	$	21.8
	Contributions to our global defined benefit pension and post-retirement health benefit plans to satisfy minimum funding requirements as well as additional discretionary funding in the aggregate were not material during the three months ended March 31, 2014, and are not expected to be material for the remainder of 2014.

Contingencies

Contingencies	3 Months Ended
	Mar. 31, 2014
Loss Contingency, Information about Litigation Matters [Abstract]	'
Contingencies [Text Block]	'
	Note 11: Contingencies
	We are a party to various legal actions and government investigations. The most significant of these are described below. It is not possible to determine the outcome of these matters and we cannot reasonably estimate the maximum potential exposure or the range of possible loss in excess of amounts accrued for any of these matters; however, we believe that, except as noted below with respect to the Alimta® patent litigation and administrative proceedings, the resolution of all such matters will not have a material adverse effect on our consolidated financial position or liquidity, but could possibly be material to our consolidated results of operations in any one accounting period.
	Alimta Patent Litigation and Administrative Proceedings
	We are engaged in various U.S. patent litigation matters involving Alimta brought pursuant to procedures set out in the Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Act). Teva Parenteral Medicines, Inc. (Teva); APP Pharmaceuticals, LLC (APP); Barr Laboratories, Inc. (Barr); Pliva Hrvatska D.O.O. (Pliva); Accord Healthcare Inc. (Accord), Apotex Inc. (Apotex), Sun Pharmaceutical Industries, Ltd. (Sun); Sun Pharma Global FZE (Sun Global); and Glenmark Generics Inc., USA (Glenmark) each submitted Abbreviated New Drug Applications (ANDAs) seeking approval to market generic versions of Alimta prior to the expiration of our vitamin dosage regimen patent (expiring in 2021 plus pediatric exclusivity expiring in 2022) and alleging the patent is invalid.
	In October 2010, we filed a lawsuit in the U.S. District Court for the Southern District of Indiana against Teva, APP, Pliva, and Barr seeking rulings that the U.S. vitamin dosage regimen patent is valid and infringed. Trial in this case occurred in August 2013. In March 2014, the court ruled that the asserted claims of the vitamin dosage patent are valid. The defendants have until April 30, 2014 to file a notice of appeal. In January 2012 and April 2012, we filed similar lawsuits in the same court against Accord and Apotex, respectively. We filed a second lawsuit against Accord in February 2013. The Accord and Apotex cases have been consolidated and stayed by the court and the parties have agreed to be bound by the outcome of the Teva/APP litigation. In September 2013, we filed a similar lawsuit in the same court against Sun and Sun Global seeking a ruling that Lilly's patent is valid and infringed. This case has been stayed, and Lilly and Sun have agreed to be bound by the outcome of the Teva/APP litigation. In January 2014, we filed a similar lawsuit in the same court against Glenmark seeking a ruling that Lilly's patent is valid and infringed. That case was amended in March 2014 to add two related Glenmark companies.
	Generic manufacturers filed an opposition to the European Patent Office's decision to grant a vitamin dosage regimen patent. The Opposition Division upheld the patent and the generic manufacturers lodged an appeal. In addition, in the UK, Actavis Group ehf and other Actavis companies filed litigation asking for a declaratory judgment that commercialization of certain salt forms of pemetrexed (the active ingredient in Alimta) would not infringe the vitamin dosage regimen patents in the UK, Italy, France, Germany, and Spain. This trial occurred in April 2014 and we are awaiting a decision. We commenced separate infringement proceedings against certain Actavis companies in Germany. The German case was heard by the trial court in March 2014. In April 2014, the German trial court ruled in favor of Lilly. The defendants have until May 5, 2014 to file their appeal.
	We believe our Alimta vitamin dosage patents are valid and enforceable against these generic manufacturers and we expect to prevail in these proceedings. However, it is not possible to determine the ultimate outcome of the proceedings, and accordingly, we can provide no assurance that we will prevail. An unfavorable outcome could have a material adverse impact on our future consolidated results of operations, liquidity, and financial position. We expect a loss of exclusivity for Alimta would result in a rapid and severe decline in future revenues in the relevant market.
	Actos® Product Liability Litigation
	We are named along with Takeda Chemical Industries, Ltd., and Takeda affiliates as a defendant in approximately 3,700 product liability cases in the U.S. related to the diabetes medication Actos, which we co-promoted with Takeda in the U.S. from 1999 until September 2006. Our agreement with Takeda calls for Takeda to defend and indemnify us against our losses and expenses with respect to the U.S. product liability litigation and other related expenses in accordance with the terms of the agreement.
	In general, plaintiffs in these actions allege that Actos caused or contributed to their bladder cancer. Almost all of the active cases have been consolidated in federal multi-district litigation in the Western District of Louisiana or are pending in a coordinated state court proceeding in California or a coordinated state court proceeding in Illinois. We believe these lawsuits are without merit, and we and Takeda are prepared to defend against them vigorously.
	On April 7, 2014, a jury in the Western District of Louisiana found in favor of the plaintiffs in the case of Terrence Allen, et al. v. Takeda Pharmaceuticals, et al., no. 6:12-md-00064. Because of the existence of the indemnification agreement, Lilly tendered its defense of the case to Takeda. The jury awarded $1.5 million in compensatory damages to plaintiffs (allocated 75 percent to Takeda and 25 percent to Lilly) and punitive damages of $6.00 billion against Takeda and $3.00 billion against Lilly. We believe the evidence did not support plaintiffs’ claims and strongly disagree with the verdict. Lilly and Takeda intend to vigorously challenge this outcome through all available legal means.
	After the jury reached a verdict in Allen, Takeda notified us that it was reserving its right to challenge its obligations to defend and indemnify us with respect to the Allen case. We believe we are entitled to full indemnification of our losses and expenses in Allen and all other U.S. cases; however, there can be no guarantee we will ultimately be successful in obtaining full indemnification.
	We are also named along with Takeda as a defendant in three purported product liability class actions in Canada related to Actos, including one in Ontario (Casseres et al. v. Takeda Pharmaceutical North America, Inc., et al.), one in Quebec (Whyte et al. v. Eli Lilly et al.), and one in Alberta (Epp v. Takeda Canada et al.). We promoted Actos in Canada until 2009. We believe these claims are without merit and are prepared to defend against them vigorously.
	Byetta Product Liability Litigation
	We are named as a defendant in approximately 340 Byetta product liability lawsuits involving approximately 770 plaintiffs. Approximately 95 of these lawsuits, covering about 490 plaintiffs, are filed in California state court and coordinated in a Los Angeles Superior Court. Approximately 220 lawsuits, covering about 225 plaintiffs are filed in federal court, the majority of which are coordinated in a multi-district litigation in the Southern District of California. The remaining approximately 25 lawsuits, representing about 60 plaintiffs, are in various state courts. Approximately 260 of the lawsuits, involving approximately 370 plaintiffs, contain allegations that Byetta caused or contributed to the plaintiffs' cancer (primarily pancreatic cancer or thyroid cancer). We are aware of approximately 460 additional claimants who have not yet filed suit. The majority of these additional claims allege damages for pancreatitis. We believe these lawsuits and claims are without merit and are prepared to defend against them vigorously.
	Prozac® Product Liability Litigation
	We are named as a defendant in approximately 10 U.S. lawsuits primarily related to allegations that the antidepressant Prozac caused or contributed to birth defects in the children of women who ingested the drug during pregnancy. We are aware of approximately 400 additional claims related to birth defects, which have not yet been filed. We believe these lawsuits and claims are without merit and are prepared to defend against them vigorously.
	Brazil–Employee Litigation
	We are named in a lawsuit brought by the Labor Attorney for 15th Region in the Labor Court of Paulinia, State of Sao Paulo, Brazil, alleging possible harm to employees and former employees caused by exposure to heavy metals at a former Lilly manufacturing facility in Cosmopolis, Brazil. Final arguments were submitted in September and we are awaiting a decision. We are also named in approximately 30 lawsuits filed in the same court by individual former employees making similar claims. We believe these lawsuits are without merit and are prepared to defend against them vigorously.
	Product Liability Insurance
	Because of the nature of pharmaceutical products, it is possible that we could become subject to large numbers of product liability and related claims in the future. Due to a very restrictive market for product liability insurance, we are self-insured for product liability losses for all our currently marketed products.

Other_Comprehensive_Income_Los

Other Comprehensive Income (Loss) (Notes)	3 Months Ended
	Mar. 31, 2014
Comprehensive Income (Loss) Note [Text Block]	'
	Note 12:    Other Comprehensive Income (Loss)
	The following tables summarize the activity related to each component of other comprehensive income (loss) during the three months ended March 31, 2014 and March 31, 2013:
	(Amounts presented net of taxes)	Foreign Currency Translation Gains (Losses)				Unrealized Net Gains (Losses) on Securities			Defined Benefit Pension and Retiree Health Benefit Plans			Effective Portion of Cash Flow Hedges			Accumulated Other Comprehensive Loss
	Balance at December 31, 2013	$	463			$	205.2		$	(2,489.1	)	$	(181.8	)	$	(2,002.7	)
	Other comprehensive income (loss) before reclassifications	(3.3		)		10.3			1.5			15.1			23.6
	Net amount reclassified from accumulated other comprehensive loss	—				(49.3		)	44.1			27			21.8
	Net other comprehensive income (loss)	(3.3		)		(39.0		)	45.6			42.1			45.4
	Balance at March 31, 2014	$	459.7			$	166.2		$	(2,443.5	)	$	(139.7	)	$	(1,957.3	)
	(Amounts presented net of taxes)	Foreign Currency Translation Gains (Losses)				Unrealized Net Gains (Losses) on Securities			Defined Benefit Pension and Retiree Health Benefit Plans			Effective Portion of Cash Flow Hedges			Accumulated Other Comprehensive Loss
	Balance at December 31, 2012	$	426.8			$	72.5		$	(4,195.2	)	$	(101.2	)	$	(3,797.1	)
	Other comprehensive income (loss) before reclassifications	(346.0		)		21.3			32.4			0.7			(291.6		)
	Net amount reclassified from accumulated other comprehensive loss	—				(3.3		)	76.1			1.5			74.3
	Net other comprehensive income (loss)	(346.0		)		18			108.5			2.2			(217.3		)
	Balance at March 31, 2013	$	80.8			$	90.5		$	(4,086.7	)	$	(99.0	)	$	(4,014.4	)
	The tax effect on the unrealized net gains (losses) on securities was a benefit of $21.2 million and an expense of $10.1 million for the three months ended March 31, 2014 and March 31, 2013, respectively. The tax effect related to our defined benefit pension and retiree health benefit plans was an expense of $23.5 million and $47.2 million for the three months ended March 31, 2014 and March 31, 2013, respectively. The tax effect on the effective portion of cash flow hedges was an expense of $22.4 million and $0.7 million for the three months ended March 31, 2014 and March 31, 2013, respectively. Income taxes are not provided for foreign currency translation.
		Reclassifications Out of Accumulated Other
		Comprehensive Loss
	Details about Accumulated Other	Three Months Ended						Affected Line Item in the Consolidated Condensed Statements of Operations
	Comprehensive Loss Components	March 31,
		2014			2013
	Amortization of defined pension benefit items:
	Prior service benefits, net	$	(6.4	)	$	(4.3	)	(1)
	Actuarial losses	74.2			119			(1)
	Total before tax	67.8			114.7
	Tax benefit	(23.7		)	(38.6		)
	Net of tax	44.1			76.1
	Other, net of tax	(22.3		)	(1.8		)	Other–net, (income) expense
	Total reclassifications for the period (net of tax)	$	21.8		$	74.3
	1	These accumulated other comprehensive loss components are included in the computation of net periodic pension cost (see Note 10).

OtherNet_Expense_Income

Other-Net, Expense (Income)	3 Months Ended
	Mar. 31, 2014
Nonoperating Income (Expense) [Abstract]	'
Other - Net, Expense (Income) [Text Block]	'
	Note 13: Other–Net, (Income) Expense
	Other–net, (income) expense consisted of the following:
		Three Months Ended
		March 31,
		2014			2013
	Interest expense	$	37.8		$	40.3
	Interest income	(34.4		)	(23.6		)
	Income related to termination of the exenatide collaboration with Amylin (Note 4)	—			(495.4		)
	Other	(59.4		)	(50.5		)
	Other–net, (income) expense	$	(56.0	)	$	(529.2	)
	Other–net, income of $529.2 million for the first three months of 2013 is primarily related to the income recognized from the transfer to Amylin of exenatide commercial rights in all markets outside the United States. See Note 4 for additional information.

Segment_Information

Segment Information	3 Months Ended
	Mar. 31, 2014
Segment Reporting [Abstract]	'
Segment Reporting Disclosure [Text Block]	'
	Note 14: Segment Information
	We operate in two business segments—human pharmaceutical products and animal health. Our business segments are distinguished by the ultimate end user of the product—humans or animals. Performance is evaluated based on profit or loss from operations before income taxes.
		Three Months Ended
		March 31,
		2014			2013
	Segment revenue—to unaffiliated customers:
	Human pharmaceutical products:
	Endocrinology	$	1,639.20		$	1,724.90
	Neuroscience	964.4			1,848.80
	Oncology	764.3			764.2
	Cardiovascular	712.8			693.9
	Other pharmaceuticals	75			71.1
	Total human pharmaceutical products	4,155.70			5,102.90
	Animal health	527.4			499.1
	Total segment revenue	$	4,683.10		$	5,602.00
	Segment profits(1):
	Human pharmaceutical products	$	787.8		$	1,348.20
	Animal health	134.4			129.2
	Total segment profits	$	922.2		$	1,477.40
	Reconciliation of total segment profits to consolidated income before taxes:
	Segment profits	$	922.2		$	1,477.40
	Other profits (losses):
	Income related to termination of the exenatide collaboration with Amylin (Note 4)	—			495.4
	Asset impairment, restructuring, and other special charges (Note 5)	(31.4		)	(21.7		)
	Total consolidated income before taxes	$	890.8		$	1,951.10
	1	Human pharmaceutical products segment profit includes total depreciation and amortization expense of $325.2 million and $355.7 million for the three months ended March 31, 2014 and 2013, respectively. Animal health segment profit includes total depreciation and amortization expense of $23.6 million and $25.8 million for the three months ended March 31, 2014 and 2013, respectively.
	For internal management reporting presented to the chief operating decision maker, certain costs are fully allocated to our human pharmaceutical products segment and therefore are not reflected in the animal health segment's profit. Such items include costs associated with treasury-related financing, global administrative services, certain acquisition-related transaction costs, and certain manufacturing costs.

Subsequent_Event_Notes

Subsequent Event (Notes)	3 Months Ended
	Mar. 31, 2014
Subsequent Event [Line Items]	'
Subsequent Events [Text Block]	'
	Note 15: Subsequent Event
	On April 22, 2014, we announced an agreement to acquire Novartis Animal Health in an all-cash transaction for approximately $5.4 billion. Novartis Animal Health has a global commercial presence in both the companion and food animal markets. Under the terms of the agreement, we will acquire manufacturing sites, R&D facilities, a global commercial infrastructure and portfolio of products, a pipeline of projects in development, and employees. The transaction is expected to close by the end of the first quarter of 2015, subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act, similar requirements outside the U.S., and other customary closing conditions.

Financial_Instruments_Policies

Financial Instruments (Policies)	3 Months Ended
	Mar. 31, 2014
Fair Value Disclosures [Abstract]	'
Description of Derivative Risk Management Policy	'Accounting Policy for Risk-Management InstrumentsOur derivative activities are initiated within the guidelines of documented corporate risk-management policies and do not create additional risk because gains and losses on derivative contracts offset losses and gains on the assets, liabilities, and transactions being hedged. As derivative contracts are initiated, we designate each instrument as either a fair value hedge or a cash flow hedge. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis.For derivative contracts that are designated and qualify as fair value hedges, the derivative instrument is marked to market with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative contracts that are designated and qualify as cash flow hedges, the effective portion of gains and losses on these contracts is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same period the hedged transaction affects earnings. Hedge ineffectiveness is immediately recognized in earnings. Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized in current earnings during the period of change.We may enter into foreign currency forward contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, the British pound, and the Japanese yen). Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures. Forward contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in otherbnet, (income) expense. We may enter into foreign currency forward contracts and currency swaps as fair value hedges of firm commitments. Forward contracts generally have maturities not exceeding 12 months.

Collaborations_Tables

Collaborations (Tables)	3 Months Ended
	Mar. 31, 2014
Erbitux [Member]	'
Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block]	'
	The following table summarizes our revenue recognized with respect to Erbitux:
		Three Months Ended
		March 31,
		2014		2013
	Net product sales	$	13.2	$	25.3
	Collaboration and other revenue	77.7		69.6
	Total revenue	$	90.9	$	94.9
Exenatide [Member]	'
Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block]	'
		Three Months Ended
		March 31,
		2014		2013
	Net product sales	$	7.6	$	64.1
	Income related to termination of the exenatide collaboration with Amylin (1)	—		495.4

Financial_Instruments_Tables

Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2014
Fair Value Disclosures [Abstract]	'
Schedule of Net Investment Hedges, Statements of Financial Performance and Financial Position, Location [Table Text Block]	'
	The following effects of risk-management instruments were recognized in other–net, (income) expense:
		Three Months Ended
		March 31,
		2014			2013
	Fair value hedges:
	Effect from hedged fixed-rate debt	$	51.8		$	(69.0	)
	Effect from interest rate contracts	(51.8		)	69
	Cash flow hedges:
	Effective portion of losses on equity contracts reclassified from accumulated other comprehensive loss(1)	39.5			—
	Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss	2.2			2.2
	Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments	(0.3		)	0.1
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	'
	The following tables summarize certain fair value information at March 31, 2014 and December 31, 2013 for assets and liabilities measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments:
									Fair Value Measurements Using
	Description	Carrying			Amortized				Quoted Prices in Active Markets for Identical Assets			Significant Other			Significant		Fair
		Amount			Cost				(Level 1)			Observable Inputs			Unobservable		Value
												(Level 2)			Inputs
															(Level 3)
	March 31, 2014
	Cash and cash equivalents	$	3,888.00		$	3,888.00			$	3,668.20		$	219.8		$		$	3,888.00
	Short-term investments:
	Government-related debt securities:
	U.S. government and agencies	$	151.1		$	151			$	151.1		$			$		$	151.1
	Foreign and other	106.8			106.8							106.8					106.8
	Corporate debt securities	841.8			838.9							841.8					841.8
	Other securities	2.5			2.5							2.5					2.5
	Marketable equity	222.2			56.3				222.2								222.2
	Short-term investments	$	1,324.40		$	1,155.50
	Noncurrent investments:
	Government-related debt securities:
	U.S. government and agencies	$	854		$	860.3			$	843.2		$	10.8		$		$	854
	Foreign and other	122.7			122.7							122.7					122.7
	Corporate debt securities	4,569.50			4,545.50							4,569.50					4,569.50
	Mortgage-backed	631.9			644							631.9					631.9
	Asset-backed	541.8			546							541.8					541.8
	Other securities	7.6			8.2							7.6					7.6
	Marketable equity	108.7			22.8				108.7								108.7
	Equity method and other investments(1)	368.6			368.6
	Noncurrent investments	$	7,204.80		$	7,118.10
	December 31, 2013
	Cash and cash equivalents	$	3,830.20		$	3,830.20			$	3,772.60		$	57.6		$		$	3,830.20
	Short-term investments:
	U.S. government and agencies	$	276.4		$	276.6			$	276.4		$			$		$	276.4
	Corporate debt securities	931.7			929.8							931.7					931.7
	Other securities	2.7			2.7							2.7					2.7
	Marketable equity	356.3			75				356.3								356.3
	Short-term investments	$	1,567.10		$	1,284.10
	Noncurrent investments:
	U.S. government and agencies	$	1,115.60		$	1,126.10			$	1,035.60		$	80		$		$	1,115.60
	Corporate debt securities	4,940.50			4,933.70							4,940.50					4,940.50
	Mortgage-backed	636			652.4							636					636
	Asset-backed	490			494.5							490					490
	Other securities	7.3			8.3							7.3					7.3
	Marketable equity	81.2			22.8				81.2								81.2
	Equity method and other investments(1)	354.3			354.3
	Noncurrent investments	$	7,624.90		$	7,592.10
Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]	'
					Fair Value Measurements Using
	Description	Carrying			Quoted Prices in Active Markets for Identical Assets		Significant				Significant	Fair
		Amount			(Level 1)		Other Observable Inputs				Unobservable	Value
							(Level 2)				Inputs
											(Level 3)
	Long-term debt, including current portion
	March 31, 2014	$	(5,264.4	)	$		$	(5,595.5	)		$	$	(5,595.5	)
	31-Dec-13	(5,212.9		)			(5,490.9		)			(5,490.9		)
Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]	'
	The table below summarizes the contractual maturities of our investments in debt securities measured at fair value as of March 31, 2014:
		Maturities by Period
		Total			Less Than				5-Feb			10-Jun			More Than
					1 Year				Years			Years			10 Years
	Fair value of debt securities	$	7,829.70		$	1,102.20			$	5,304.30		$	662.2		$	761
Fair Value, by Balance Sheet Grouping [Table Text Block]	'
					Fair Value Measurements Using
	Description	Carrying			Quoted Prices in Active Markets for Identical Assets		Significant				Significant	Fair
		Amount			(Level 1)		Other Observable Inputs				Unobservable	Value
							(Level 2)				Inputs
											(Level 3)
	March 31, 2014
	Risk-management instruments
	Interest rate contracts designated as hedging instruments:
	Sundry	$	334.1				$	334.1				$	334.1
	Other noncurrent liabilities	(1.2		)			(1.2		)			(1.2		)
	Foreign exchange contracts not designated as hedging instruments:
	Other receivables	6.4					6.4					6.4
	Other current liabilities	(8.0		)			(8.0		)			(8.0		)
	Equity contracts designated as hedging instruments:
	Other current liabilities	(63.7		)			(63.7		)			(63.7		)
	December 31, 2013
	Risk-management instruments
	Interest rate contracts designated as hedging instruments:
	Other receivables	20.1					20.1					20.1
	Sundry	278.7					278.7					278.7
	Other noncurrent liabilities	(0.9		)			(0.9		)			(0.9		)
	Foreign exchange contracts not designated as hedging instruments:
	Other receivables	6.7					6.7					6.7
	Other current liabilities	(7.1		)			(7.1		)			(7.1		)
	Equity contracts designated as hedging instruments:
	Other current liabilities	(149.6		)			(149.6		)			(149.6		)
Available-for-sale Securities [Table Text Block]	'
	A summary of the fair value of available-for-sale securities in an unrealized gain or loss position and the amount of unrealized gains and losses (pretax) in accumulated other comprehensive loss follows:
		March 31, 2014			December 31, 2013
	Unrealized gross gains	$	293.9		$	375.6
	Unrealized gross losses	38.3			59.8
	Fair value of securities in an unrealized gain position	5,356.00			4,982.70
	Fair value of securities in an unrealized loss position	2,607.60			3,664.70
Gain (Loss) on Investments [Table Text Block]	'
	Activity related to our investment portfolio, substantially all of which related to available-for-sale securities, was as follows:
		Three Months Ended
		March 31,
		2014			2013
	Proceeds from sales	$	3,742.20		$	3,705.90
	Realized gross gains on sales	79.8			10
	Realized gross losses on sales	4			2.5

Retirement_Benefits_Tables

Retirement Benefits (Tables)	3 Months Ended
	Mar. 31, 2014
Schedule of Net Benefit Costs [Table Text Block]	'
	Net pension and retiree health benefit expense included the following components:
		Defined Benefit Pension Plans						Retiree Health Benefit Plans
		Three Months Ended						Three Months Ended
		March 31,						March 31,
		2014			2013			2014			2013
	Components of net periodic benefit cost:
	Service cost	$	62.7		$	69.7		$	11.3		$	15.1
	Interest cost	119.2			109.4			21.2			23.4
	Expected return on plan assets	(189.3		)	(174.9		)	(36.0		)	(32.8		)
	Amortization of prior service cost (benefit)	0.9			2.6			(7.3		)	(6.9		)
	Recognized actuarial loss	69.1			96			5.1			23
	Net periodic benefit cost (benefit)	$	62.6		$	102.8		$	(5.7	)	$	21.8

Other_Comprehensive_Income_Los1

Other Comprehensive Income (Loss) (Tables)	3 Months Ended
	Mar. 31, 2014																	Mar. 31, 2013
Statement of Comprehensive Income [Abstract]	'																	'
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	'																	'
	The following tables summarize the activity related to each component of other comprehensive income (loss) during the three months ended March 31, 2014 and March 31, 2013:
																		(Amounts presented net of taxes)	Foreign Currency Translation Gains (Losses)			Unrealized Net Gains (Losses) on Securities			Defined Benefit Pension and Retiree Health Benefit Plans			Effective Portion of Cash Flow Hedges			Accumulated Other Comprehensive Loss
	(Amounts presented net of taxes)	Foreign Currency Translation Gains (Losses)				Unrealized Net Gains (Losses) on Securities			Defined Benefit Pension and Retiree Health Benefit Plans			Effective Portion of Cash Flow Hedges			Accumulated Other Comprehensive Loss			Balance at December 31, 2012	$	426.8		$	72.5		$	(4,195.2	)	$	(101.2	)	$	(3,797.1	)
	Balance at December 31, 2013	$	463			$	205.2		$	(2,489.1	)	$	(181.8	)	$	(2,002.7	)
																		Other comprehensive income (loss) before reclassifications	(346.0		)	21.3			32.4			0.7			(291.6		)
	Other comprehensive income (loss) before reclassifications	(3.3		)		10.3			1.5			15.1			23.6
																		Net amount reclassified from accumulated other comprehensive loss	—			(3.3		)	76.1			1.5			74.3
	Net amount reclassified from accumulated other comprehensive loss	—				(49.3		)	44.1			27			21.8
																		Net other comprehensive income (loss)	(346.0		)	18			108.5			2.2			(217.3		)
	Net other comprehensive income (loss)	(3.3		)		(39.0		)	45.6			42.1			45.4
																		Balance at March 31, 2013	$	80.8		$	90.5		$	(4,086.7	)	$	(99.0	)	$	(4,014.4	)
	Balance at March 31, 2014	$	459.7			$	166.2		$	(2,443.5	)	$	(139.7	)	$	(1,957.3	)
Schedule of Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block]	'																	'
		Reclassifications Out of Accumulated Other
		Comprehensive Loss
	Details about Accumulated Other	Three Months Ended						Affected Line Item in the Consolidated Condensed Statements of Operations
	Comprehensive Loss Components	March 31,
		2014			2013
	Amortization of defined pension benefit items:
	Prior service benefits, net	$	(6.4	)	$	(4.3	)	(1)
	Actuarial losses	74.2			119			(1)
	Total before tax	67.8			114.7
	Tax benefit	(23.7		)	(38.6		)
	Net of tax	44.1			76.1
	Other, net of tax	(22.3		)	(1.8		)	Other–net, (income) expense
	Total reclassifications for the period (net of tax)	$	21.8		$	74.3

Other_Net_Expense_Income_Table

Other - Net, Expense (Income) (Tables)	3 Months Ended
	Mar. 31, 2014
Nonoperating Income (Expense) [Abstract]	'
Schedule of Other Nonoperating Income (Expense) [Table Text Block]	'
	Other–net, (income) expense consisted of the following:
		Three Months Ended
		March 31,
		2014			2013
	Interest expense	$	37.8		$	40.3
	Interest income	(34.4		)	(23.6		)
	Income related to termination of the exenatide collaboration with Amylin (Note 4)	—			(495.4		)
	Other	(59.4		)	(50.5		)
	Other–net, (income) expense	$	(56.0	)	$	(529.2	)

Segment_Information_Tables

Segment Information (Tables)	3 Months Ended
	Mar. 31, 2014
Segment Reporting [Abstract]	'
Segment Information [Text Block]	'
		Three Months Ended
		March 31,
		2014			2013
	Segment revenue—to unaffiliated customers:
	Human pharmaceutical products:
	Endocrinology	$	1,639.20		$	1,724.90
	Neuroscience	964.4			1,848.80
	Oncology	764.3			764.2
	Cardiovascular	712.8			693.9
	Other pharmaceuticals	75			71.1
	Total human pharmaceutical products	4,155.70			5,102.90
	Animal health	527.4			499.1
	Total segment revenue	$	4,683.10		$	5,602.00
	Segment profits(1):
	Human pharmaceutical products	$	787.8		$	1,348.20
	Animal health	134.4			129.2
	Total segment profits	$	922.2		$	1,477.40
	Reconciliation of total segment profits to consolidated income before taxes:
	Segment profits	$	922.2		$	1,477.40
	Other profits (losses):
	Income related to termination of the exenatide collaboration with Amylin (Note 4)	—			495.4
	Asset impairment, restructuring, and other special charges (Note 5)	(31.4		)	(21.7		)
	Total consolidated income before taxes	$	890.8		$	1,951.10

Acquisitions_Details

Acquisitions (Details) (Lohmann Animal Health [Member], EUR €)	1 Months Ended
In Millions, unless otherwise specified	Feb. 28, 2014
Lohmann Animal Health [Member]	'
Business Combination, Consideration Transferred	€ 440

Collaborations_Details

Collaborations (Details)

1 Months Ended

3 Months Ended

1 Months Ended

10 Months Ended

1 Months Ended

1 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

6 Months Ended

1 Months Ended

6 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

Aug. 31, 2012

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Oct. 31, 2013

Nov. 30, 2011

Oct. 31, 2011

Aug. 31, 2012

Nov. 30, 2011

Nov. 30, 2011

Nov. 30, 2011

Nov. 30, 2011

Jun. 30, 2001

Dec. 31, 2009

Nov. 30, 2011

Mar. 31, 2011

Dec. 31, 2013

Dec. 31, 2011

Mar. 31, 2011

Dec. 31, 2013

Dec. 31, 2009

Dec. 31, 2012

Oct. 31, 2013

Jun. 30, 2011

Dec. 31, 2009

Oct. 31, 2013

Jun. 30, 2011

Dec. 31, 2009

Jun. 30, 2011

Nov. 30, 2011

USD ($)

USD ($)

USD ($)

Erbitux [Member]

Erbitux [Member]

Effient [Member]

Effient [Member]

Amylin [Member]

Amylin [Member]

Exenatide [Member]

Exenatide [Member]

Boerhringer Ingelheim (BI) [Member]

Boerhringer Ingelheim (BI) [Member]

Tanezumab [Member]

Sales [Member]

Sales [Member]

Revenue Share [Member]

Revenue Share [Member]

Revenue Share [Member]

Revenue Share [Member]

Secured Note [Member]

Profit and Development and Marketing Share [Member]

Research and Development Exp [Member]

Milestone Payments, Development and Regulatory [Member]

Milestone Payments, Development and Regulatory [Member]

Milestone Payments, Development and Regulatory [Member]

Milestone Payments, Development and Regulatory [Member]

Milestone Payments, Development and Regulatory [Member]

Milestone Payments, Development and Regulatory [Member]

Milestone Payments, Development and Regulatory [Member]

Milestone Payments, Development and Regulatory [Member]

Milestone Payments, Development and Regulatory [Member]

Milestone Payments, Sales-based [Member]

Milestone Payments, Sales-based [Member]

Milestone Payments, Sales-based [Member]

Royalty Agreement Terms [Member]

Royalty Agreement Terms [Member]

Loan Commitment [Member]

Upfront Payment [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Amylin [Member]

Outside the United States [Member]

Amylin [Member]

Amylin [Member]

United States [Member]

Outside the United States [Member]

Amylin [Member]

Effient [Member]

Baricitinib [Member]

Amylin [Member]

BI compounds [Member]

BI compounds [Member]

BI compounds [Member]

LLY compounds [Member]

LLY compounds [Member]

Baricitinib [Member]

Baricitinib [Member]

Tanezumab [Member]

TPG-Axon [Member]

Baricitinib [Member]

Tanezumab [Member]

Solanezumab [Member]

Baricitinib [Member]

Exenatide Once Weekly [Member]

Amylin [Member]

Exenatide [Member]

USD ($)

USD ($)

Amylin [Member]

Amylin [Member]

USD ($)

EUR (€)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Net product sales

'

'

'

$13,200,000

$25,300,000

$119,300,000

$115,900,000

'

'

$7,600,000

$64,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Collaboration and other revenue

'

181,200,000

153,500,000

77,700,000

69,600,000

'

'

'

'

'

'

76,900,000

42,600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Revenue

'

4,683,100,000

5,602,000,000

90,900,000

94,900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Income related to the termination of the exenatide collaboratio

'

0

495,400,000

'

'

'

'

0

495,400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Research and development

'

1,109,300,000

1,348,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Collaborative Arrangement, Income Statement Classification and Amounts

'

48,000,000

45,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Collaborative Arrangement, Rights and Obligations, Terms

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,260,000,000

1,200,000,000

'

'

'

'

'

150,000,000

-225,000,000

-97,200,000

-478,700,000

-250,000,000

-50,000,000

-415,000,000

-50,000,000

-350,000,000

-70,000,000

-150,000,000

-1,230,000,000

'

'

-165,000,000

250,000,000

Collaborative Arrangement, Rights and Obligations, Terms of Arrangement, Period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'

'

'

Debt Instrument, Interest Rate, Stated Percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

9.50%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Collaborative Arrangement, Rights and Obligations Percent

'

'

'

'

'

'

'

'

'

'

'

'

'

'

15.00%

100.00%

'

'

65.00%

35.00%

'

50.00%

30.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

20.00%

'

'

Proceeds from prepayment of revenue-sharing obligation

1,210,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Acquired in-process research and development

'

'

'

'

'

'

'

'

'

'

'

'

'

200,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amortization of Intangible Assets

'

$131,900,000

$146,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Asset_Impairments_Restructurin1

Asset Impairments, Restructuring, and Other Special Charges (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Unusual or Infrequent Item [Line Items]	'	'
Asset impairment, restructuring, and other special charges	$31.40	$21.70

Financial_Instruments_Details

Financial Instruments (Details)

3 Months Ended

12 Months Ended

3 Months Ended

In Millions, unless otherwise specified

Mar. 31, 2014

Mar. 31, 2013

Dec. 31, 2013

Mar. 31, 2014

Feb. 28, 2014

Mar. 31, 2014

Feb. 28, 2014

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

USD ($)

USD ($)

USD ($)

Due 2019 [Member]

Due 2019 [Member]

Due 2044 [Member]

Due 2044 [Member]

Equity Contract [Member]

Equity Contract [Member]

Hedged Fixed-Rate Debt [Member]

Hedged Fixed-Rate Debt [Member]

Interest Rate Contract [Member]

Interest Rate Contract [Member]

Carrying (Reported) Amount, Fair Value Disclosure [Member]

Carrying (Reported) Amount, Fair Value Disclosure [Member]

Carrying (Reported) Amount, Fair Value Disclosure [Member]

Carrying (Reported) Amount, Fair Value Disclosure [Member]

Carrying (Reported) Amount, Fair Value Disclosure [Member]

Carrying (Reported) Amount, Fair Value Disclosure [Member]

Carrying (Reported) Amount, Fair Value Disclosure [Member]

Carrying (Reported) Amount, Fair Value Disclosure [Member]

Available-for-Sale Securities, Amortized Cost [Member]

Available-for-Sale Securities, Amortized Cost [Member]

Fair Value, Inputs, Level 1 [Member]

Fair Value, Inputs, Level 1 [Member]

Fair Value, Inputs, Level 2 [Member]

Fair Value, Inputs, Level 2 [Member]

Fair Value, Inputs, Level 2 [Member]

Fair Value, Inputs, Level 2 [Member]

Fair Value, Inputs, Level 2 [Member]

Fair Value, Inputs, Level 2 [Member]

Fair Value, Inputs, Level 2 [Member]

Fair Value, Inputs, Level 2 [Member]

Estimate of Fair Value, Fair Value Disclosure [Member]

Estimate of Fair Value, Fair Value Disclosure [Member]

Estimate of Fair Value, Fair Value Disclosure [Member]

Estimate of Fair Value, Fair Value Disclosure [Member]

Estimate of Fair Value, Fair Value Disclosure [Member]

Estimate of Fair Value, Fair Value Disclosure [Member]

Estimate of Fair Value, Fair Value Disclosure [Member]

Estimate of Fair Value, Fair Value Disclosure [Member]

Corporate Debt Securities [Member]

Corporate Debt Securities [Member]

Corporate Debt Securities [Member]

Corporate Debt Securities [Member]

Corporate Debt Securities [Member]

Corporate Debt Securities [Member]

Corporate Debt Securities [Member]

Corporate Debt Securities [Member]

US Government Agencies Debt Securities [Member]

US Government Agencies Debt Securities [Member]

US Government Agencies Debt Securities [Member]

US Government Agencies Debt Securities [Member]

US Government Agencies Debt Securities [Member]

US Government Agencies Debt Securities [Member]

US Government Agencies Debt Securities [Member]

US Government Agencies Debt Securities [Member]

US Government Agencies Debt Securities [Member]

US Government Agencies Debt Securities [Member]

Foreign Government Debt Securities [Member]

Foreign Government Debt Securities [Member]

Foreign Government Debt Securities [Member]

Foreign Government Debt Securities [Member]

Other Debt Obligations [Member]

Other Debt Obligations [Member]

Other Debt Obligations [Member]

Other Debt Obligations [Member]

Other Debt Obligations [Member]

Other Debt Obligations [Member]

Other Debt Obligations [Member]

Other Debt Obligations [Member]

Collateralized Mortgage Backed Securities [Member]

Collateralized Mortgage Backed Securities [Member]

Collateralized Mortgage Backed Securities [Member]

Collateralized Mortgage Backed Securities [Member]

Collateralized Mortgage Backed Securities [Member]

Collateralized Mortgage Backed Securities [Member]

Collateralized Mortgage Backed Securities [Member]

Collateralized Mortgage Backed Securities [Member]

Asset-backed Securities [Member]

Asset-backed Securities [Member]

Asset-backed Securities [Member]

Asset-backed Securities [Member]

Asset-backed Securities [Member]

Asset-backed Securities [Member]

Asset-backed Securities [Member]

Asset-backed Securities [Member]

Equity Securities, US [Member]

Equity Securities, US [Member]

Equity Securities, US [Member]

Equity Securities, US [Member]

Equity Securities, US [Member]

Equity Securities, US [Member]

Equity Securities, US [Member]

Equity Securities, US [Member]

Equity Method and Other Investments [Member]

Equity Method and Other Investments [Member]

Equity Method and Other Investments [Member]

Equity Method and Other Investments [Member]

Buy British pound Sell euro [Member]

Buy British pound Sell euro [Member]

Buy US dollar Sell euro [Member]

Buy US dollar Sell euro [Member]

Buy euro Sell US dollar [Member]

Buy euro Sell US dollar [Member]

Buy US dollar Sell Japanese Yen [Member]

Buy US dollar Sell Japanese Yen [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Equity Contract [Member]

Equity Contract [Member]

Interest Rate Contract [Member]

Interest Rate Contract [Member]

Foreign Exchange Contract [Member]

Foreign Exchange Contract [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Equity Contract [Member]

Equity Contract [Member]

Interest Rate Contract [Member]

Interest Rate Contract [Member]

Foreign Exchange Contract [Member]

Foreign Exchange Contract [Member]

USD ($)

USD ($)

Equity Contract [Member]

Equity Contract [Member]

Interest Rate Contract [Member]

Interest Rate Contract [Member]

Foreign Exchange Contract [Member]

Foreign Exchange Contract [Member]

Carrying (Reported) Amount, Fair Value Disclosure [Member]

Carrying (Reported) Amount, Fair Value Disclosure [Member]

Available-for-Sale Securities, Amortized Cost [Member]

Available-for-Sale Securities, Amortized Cost [Member]

Fair Value, Inputs, Level 2 [Member]

Fair Value, Inputs, Level 2 [Member]

Estimate of Fair Value, Fair Value Disclosure [Member]

Estimate of Fair Value, Fair Value Disclosure [Member]

Carrying (Reported) Amount, Fair Value Disclosure [Member]

Carrying (Reported) Amount, Fair Value Disclosure [Member]

Available-for-Sale Securities, Amortized Cost [Member]

Available-for-Sale Securities, Amortized Cost [Member]

Fair Value, Inputs, Level 1 [Member]

Fair Value, Inputs, Level 1 [Member]

Fair Value, Inputs, Level 2 [Member]

Fair Value, Inputs, Level 2 [Member]

Estimate of Fair Value, Fair Value Disclosure [Member]

Estimate of Fair Value, Fair Value Disclosure [Member]

USD ($)

Available-for-Sale Securities, Amortized Cost [Member]

Fair Value, Inputs, Level 2 [Member]

Estimate of Fair Value, Fair Value Disclosure [Member]

Carrying (Reported) Amount, Fair Value Disclosure [Member]

Carrying (Reported) Amount, Fair Value Disclosure [Member]

Available-for-Sale Securities, Amortized Cost [Member]

Available-for-Sale Securities, Amortized Cost [Member]

Fair Value, Inputs, Level 2 [Member]

Fair Value, Inputs, Level 2 [Member]

Estimate of Fair Value, Fair Value Disclosure [Member]

Estimate of Fair Value, Fair Value Disclosure [Member]

Carrying (Reported) Amount, Fair Value Disclosure [Member]

Carrying (Reported) Amount, Fair Value Disclosure [Member]

Available-for-Sale Securities, Amortized Cost [Member]

Available-for-Sale Securities, Amortized Cost [Member]

Fair Value, Inputs, Level 2 [Member]

Fair Value, Inputs, Level 2 [Member]

Estimate of Fair Value, Fair Value Disclosure [Member]

Estimate of Fair Value, Fair Value Disclosure [Member]

Carrying (Reported) Amount, Fair Value Disclosure [Member]

Carrying (Reported) Amount, Fair Value Disclosure [Member]

Available-for-Sale Securities, Amortized Cost [Member]

Available-for-Sale Securities, Amortized Cost [Member]

Fair Value, Inputs, Level 2 [Member]

Fair Value, Inputs, Level 2 [Member]

Estimate of Fair Value, Fair Value Disclosure [Member]

Estimate of Fair Value, Fair Value Disclosure [Member]

Carrying (Reported) Amount, Fair Value Disclosure [Member]

Carrying (Reported) Amount, Fair Value Disclosure [Member]

Available-for-Sale Securities, Amortized Cost [Member]

Available-for-Sale Securities, Amortized Cost [Member]

Fair Value, Inputs, Level 1 [Member]

Fair Value, Inputs, Level 1 [Member]

Estimate of Fair Value, Fair Value Disclosure [Member]

Estimate of Fair Value, Fair Value Disclosure [Member]

Carrying (Reported) Amount, Fair Value Disclosure [Member]

Carrying (Reported) Amount, Fair Value Disclosure [Member]

Available-for-Sale Securities, Amortized Cost [Member]

Available-for-Sale Securities, Amortized Cost [Member]

EUR (€)

GBP (£)

USD ($)

EUR (€)

USD ($)

EUR (€)

USD ($)

JPY (¥)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Repayments of Long-term Debt

$1,002

$0.90

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Available-for-sale Securities, Debt Securities

7,829.70

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge

'

'

'

'

'

'

'

'

'

51.8

-69

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash and Cash Equivalents, Fair Value Disclosure

'

'

'

'

'

'

'

'

'

'

'

'

'

3,888

3,830.20

'

'

'

'

'

'

3,888

3,830.20

3,668.20

3,772.60

219.8

57.6

'

'

'

'

'

'

3,888

3,830.20

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Long-term Debt

'

'

'

'

-600

'

-400

'

'

'

'

'

'

-5,264.40

-5,212.90

'

'

'

'

'

'

'

'

'

'

-5,595.50

-5,490.90

'

'

'

'

'

'

-5,595.50

-5,490.90

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Interest Rate, Stated Percentage

'

'

'

1.95%

'

4.65%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Derivative Assets, Current

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20.1

6.4

6.7

'

'

'

'

'

'

'

'

'

20.1

6.4

6.7

'

'

'

'

'

20.1

6.4

6.7

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Other, Percentage of Nonperforming Assets

85.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum Remaining Maturity of Foreign Currency Derivatives

'30 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Description of Derivative Activity Volume Percent

50.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments

'

'

'

'

'

'

'

'

'

'

'

-51.8

69

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net

9

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Derivative Instruments, Loss Reclassified from Accumulated OCI into Income, Effective Portion

'

'

'

'

'

'

'

39.5

0

'

'

2.2

2.2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Derivative Instruments, Gain (Loss) Recognized in Income, Net

-0.3

0.1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net

'

'

'

'

'

'

'

85.9

1.1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Derivative Assets, Noncurrent

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

334.1

278.7

'

'

'

'

'

'

'

'

'

'

334.1

278.7

'

'

'

'

'

'

334.1

278.7

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Derivative Liabilities, Current

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-63.7

-149.6

'

'

-8

-7.1

'

'

'

'

'

'

-63.7

-149.6

'

'

-8

-7.1

'

'

-63.7

-149.6

'

'

-8

-7.1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Derivative Liabilities, Noncurrent

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-1.2

-0.9

'

'

'

'

'

'

'

'

'

'

-1.2

-0.9

'

'

'

'

'

'

-1.2

-0.9

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Available-for-sale Securities, Debt Maturities, Year Two Through Five, Fair Value

5,304.30

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Available-for-sale Securities, Gross Unrealized Gains

293.9

'

375.6

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Available-for-sale Securities, Gross Unrealized Losses

38.3

'

59.8

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Available-for-sale Securities, Continuous Unrealized Gain Position, Fair Value

5,356

'

4,982.70

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value

2,607.60

'

3,664.70

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Other than Temporary Impairment Losses, Investments

0

5.2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Sale and Maturity of Available-for-sale Securities

3,742.20

3,705.90

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Available-for-sale Securities, Gross Realized Gains

79.8

10

'

'

'

'

'

69

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Available-for-sale Securities, Gross Realized Losses

4

2.5

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Available-for-sale Securities, Current [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Available-for-sale Securities, Debt Securities, Current

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

841.8

931.7

838.9

929.8

841.8

931.7

841.8

931.7

151.1

276.4

151

276.6

151.1

276.4

'

'

151.1

276.4

106.8

106.8

106.8

106.8

2.5

2.7

2.5

2.7

2.5

2.7

2.5

2.7

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Available-for-sale Securities, Equity Securities, Current

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

222.2

356.3

56.3

75

222.2

356.3

222.2

356.3

'

'

'

'

'

'

'

'

'

'

'

'

Available-for-sale Securities, Current, Total

'

'

'

'

'

'

'

'

'

'

'

'

'

1,324.40

1,567.10

'

'

'

'

'

'

1,155.50

1,284.10

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Available-for-sale Securities, Noncurrent [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Available-for-sale Securities, Debt Securities, Noncurrent

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,569.50

4,940.50

4,545.50

4,933.70

4,569.50

4,940.50

4,569.50

4,940.50

854

1,115.60

860.3

1,126.10

843.2

1,035.60

10.8

80

854

1,115.60

122.7

122.7

122.7

122.7

7.6

7.3

8.2

8.3

7.6

7.3

7.6

7.3

631.9

636

644

652.4

631.9

636

631.9

636

541.8

490

546

494.5

541.8

490

541.8

490

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Available-for-sale Securities, Equity Securities, Noncurrent

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

108.7

81.2

22.8

22.8

108.7

81.2

108.7

81.2

'

'

'

'

'

'

'

'

'

'

'

'

Other Long-term Investments

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

368.6

354.3

368.6

354.3

'

'

'

'

'

'

'

'

Available-for-sale Securities, Noncurrent, Total

'

'

'

'

'

'

'

'

'

'

'

'

'

7,204.80

7,624.90

'

'

'

'

'

'

7,118.10

7,592.10

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Available-for-sale Securities, Debt Maturities, Next Twelve Months, Fair Value

1,102.20

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Available-for-sale Securities, Debt Maturities, Year Six Through Ten, Fair Value

662.2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Available-for-sale Securities, Debt Maturities, after Ten Years, Fair Value

761

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Derivative Liability, Notional Amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100.6

290.4

'

'

422.7

269.2

'

Derivative Asset, Notional Amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

€ 120.20

'

'

€ 209.90

$585.80

'

'

¥ 27,470

StockBased_Compensation_Detail

Stock-Based Compensation (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Allocated Share-based Compensation Expense	$38.30	$35.20
Stock-based compensation expense	38.3	35.2
Performance Awards, General [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	'2 years	'
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized	49.7	'
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition	'17 months	'
Shareholder Value Awards [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	'3 years	'
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized	95.1	'
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition	'26 months	'
Restricted Stock Units (RSUs) [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	'3 years	'
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized	$103	'
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition	'27 months	'

Shareholders_Equity_Details

Shareholders' Equity (Details) (USD $)	1 Months Ended	3 Months Ended		12 Months Ended
	Oct. 31, 2013	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2012
Stockholders' Equity Note [Abstract]	'	'	'	'
Treasury Stock, Value, Acquired, Cost Method	'	$55,000,000	$1,100,000,000	'
Stock Repurchase Program, Authorized Amount	$5,000,000,000	'	'	$1,500,000,000

Income_Taxes_Income_Taxes_Deta

Income Taxes Income Taxes (Details)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Income Tax Examination [Line Items]	'	'	'
Income Tax Examination, Year under Examination	'2012	'2011	'2010

Retirement_Benefits_Details

Retirement Benefits (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Pension Plans, Defined Benefit [Member]	'	'
Defined Benefit Plan, Service Cost	$62.70	$69.70
Defined Benefit Plan, Interest Cost	119.2	109.4
Defined Benefit Plan, Expected Return on Plan Assets	-189.3	-174.9
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)	0.9	2.6
Defined Benefit Plan, Actuarial Gain (Loss)	69.1	96
Defined Benefit Plan, Net Periodic Benefit Cost, Total	62.6	102.8
Other Postretirement Benefit Plans, Defined Benefit [Member]	'	'
Defined Benefit Plan, Service Cost	11.3	15.1
Defined Benefit Plan, Interest Cost	21.2	23.4
Defined Benefit Plan, Expected Return on Plan Assets	-36	-32.8
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)	-7.3	-6.9
Defined Benefit Plan, Actuarial Gain (Loss)	5.1	23
Defined Benefit Plan, Net Periodic Benefit Cost, Total	($5.70)	$21.80

Contingencies_Details

Contingencies (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014
Compensatory Damages [Member] | Actos [Member]	'
Loss Contingency, Damages Awarded, Value	$1.50
Punitive Damages Lilly [Member] | Actos [Member]	'
Loss Contingency, Damages Awarded, Value	3,000
Punitive Damages Takeda [Member] | Actos [Member]	'
Loss Contingency, Damages Awarded, Value	$6,000
Multi District Litigation MDL [Member] | Byetta [Member]	'
Loss Contingency, Number of Lawsuits	220
Loss Contingency, Number of Plaintiffs	225
Product Liability Litigation [Member] | Byetta [Member]	'
Loss Contingency, Number of Lawsuits	340
Loss Contingency, Number of Plaintiffs	770
Loss Contingency, Number of Claimants	460
Product Liability Litigation [Member] | Prozac [Member]	'
Loss Contingency, Number of Lawsuits	10
Loss Contingency, Number of Claimants	400
Product Liability Litigation [Member] | Actos [Member]	'
Loss Contingency, Number of Cases	3,700
Product Liability Litigation [Member] | Damages from Product, Cancer [Member] | Byetta [Member]	'
Loss Contingency, Number of Lawsuits	260
Loss Contingency, Number of Plaintiffs	370
Product Liability Litigation [Member] | CANADA | Actos [Member]	'
Loss Contingency, Number of Cases	3
Product Liability Litigation [Member] | ONTARIO | Actos [Member]	'
Loss Contingency, Number of Cases	1
Product Liability Litigation [Member] | QUEBEC | Actos [Member]	'
Loss Contingency, Number of Cases	1
Product Liability Litigation [Member] | ALBERTA | Actos [Member]	'
Loss Contingency, Number of Cases	1
Product Liability Litigation [Member] | CALIFORNIA | Byetta [Member]	'
Loss Contingency, Number of Lawsuits	95
Loss Contingency, Number of Plaintiffs	490
Product Liability Litigation [Member] | Other states [Member] | Byetta [Member]	'
Loss Contingency, Number of Lawsuits	25
Loss Contingency, Number of Plaintiffs	60
Lilly Portion [Member] | Compensatory Damages [Member] | Actos [Member]	'
Loss Contingency, Parties Jointly and Severally Liable in Litigation, Percent Share	25.00%
Takeda Portion [Member] | Compensatory Damages [Member] | Actos [Member]	'
Loss Contingency, Parties Jointly and Severally Liable in Litigation, Percent Share	75.00%
Employee Litigation [Member] | Brazil [Member]	'
Loss Contingency, Number of Lawsuits	30

Other_Comprehensive_Income_Los2

Other Comprehensive Income (Loss) (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013	Dec. 31, 2012
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Net Prior Service Cost Arising During Period, before Tax	($6.40)	($4.30)	'	'
Accumulated other comprehensive loss	-1,957.30	-4,014.40	-2,002.70	-3,797.10
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax	23.6	-291.6	'	'
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment Realized upon Sale or Liquidation, Net of Tax	21.8	74.3	'	'
Other comprehensive income (loss), net of tax	45.4	-217.3	'	'
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Net Unamortized Gain (Loss) Arising During Period, before Tax	74.2	119	'	'
Other Comprehensive Income (Loss), Reclassification, Pension and Other Postretirement Benefit Plans, Net Gain (Loss) Recognized in Net Periodic Benefit Cost, before Tax	67.8	114.7	'	'
Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net (Gain) Loss, Tax	-23.7	-38.6	'	'
Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net (Gain) Loss, Net of Tax	44.1	76.1	'	'
Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Tax	21.2	-10.1	'	'
Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, before Reclassification Adjustments, Tax	23.5	47.2	'	'
Other Comprehensive Income, Other, Net of Tax	-22.3	-1.8	'	'
Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax	22.4	0.7	'	'
Accumulated Translation Adjustment [Member]	'	'	'	'
Accumulated other comprehensive loss	459.7	80.8	463	426.8
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax	-3.3	-346	'	'
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment Realized upon Sale or Liquidation, Net of Tax	0	0	'	'
Other comprehensive income (loss), net of tax	-3.3	-346	'	'
Accumulated Net Unrealized Investment Gain (Loss) [Member]	'	'	'	'
Accumulated other comprehensive loss	166.2	90.5	205.2	72.5
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax	10.3	21.3	'	'
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment Realized upon Sale or Liquidation, Net of Tax	-49.3	-3.3	'	'
Other comprehensive income (loss), net of tax	-39	18	'	'
Accumulated Defined Benefit Plans Adjustment [Member]	'	'	'	'
Accumulated other comprehensive loss	-2,443.50	-4,086.70	-2,489.10	-4,195.20
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax	1.5	32.4	'	'
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment Realized upon Sale or Liquidation, Net of Tax	44.1	76.1	'	'
Other comprehensive income (loss), net of tax	45.6	108.5	'	'
Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member]	'	'	'	'
Accumulated other comprehensive loss	-139.7	-99	-181.8	-101.2
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax	15.1	0.7	'	'
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment Realized upon Sale or Liquidation, Net of Tax	27	1.5	'	'
Other comprehensive income (loss), net of tax	$42.10	$2.20	'	'

Other_Net_Expense_Income_Detai

Other - Net, Expense (Income) (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Income related to the termination of the exenatide collaboration	$0	($495.40)
Interest Expense	37.8	40.3
Investment Income, Interest	-34.4	-23.6
Other (income)expense	-59.4	-50.5
Nonoperating Income (Expense), Total	-56	-529.2
Amylin [Member]	'	'
Income related to the termination of the exenatide collaboration	$0	($495.40)

Segment_Information_Details

Segment Information (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Depreciation and amortization	$348.80	$381.50
Revenue	4,683.10	5,602
Segment Reporting Information, Income (Loss) before Income Taxes	890.8	1,951.10
Income related to the termination of the exenatide collaboratio	0	495.4
Asset impairment, restructuring, and other special charges	-31.4	-21.7
Neuroscience [Member]	'	'
Revenue	964.4	1,848.80
Endocrinology [Member]	'	'
Revenue	1,639.20	1,724.90
Oncology [Member]	'	'
Revenue	764.3	764.2
Cardiovascular [Member]	'	'
Revenue	712.8	693.9
Animal health [Member]	'	'
Depreciation and amortization	23.6	25.8
Revenue	527.4	499.1
Segment Reporting Information, Income (Loss) before Income Taxes	134.4	129.2
Other pharmaceuticals [Member]	'	'
Revenue	75	71.1
Pharmaceutical products, total [Member]	'	'
Depreciation and amortization	325.2	355.7
Revenue	4,155.70	5,102.90
Segment Reporting Information, Income (Loss) before Income Taxes	787.8	1,348.20
Total segment [Member]	'	'
Segment Reporting Information, Income (Loss) before Income Taxes	922.2	1,477.40
Amylin [Member]	'	'
Income related to the termination of the exenatide collaboratio	$0	$495.40

Subsequent_Event_Details

Subsequent Event (Details) (Subsequent Event [Member], USD $)	1 Months Ended
In Millions, unless otherwise specified	Apr. 30, 2014
Subsequent Event [Member]	'
Subsequent Event [Line Items]	'
Business Combination, Consideration Transferred	$5,400